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1. Abbreviations  
ABRS Acute bacterial rhinosinusitis 
AERD Aspirin exacerbated respiratory disease 
AET Acid exposure time 
AR Allergic rhinitis 
ARS Acute rhinosinusitis 
ASA Acetyl salicylic acid 
BMI Body Mass Index 
COX Cyclooxygenase 
CRS Chronic rhino sinusitis 
CRSwNP Chronic rhino sinusitis with nasal polyps 
CRSsNP Chronic rhino sinusitis sin nasal polyps 
CT Computer tomography 
EER Extraesophageal reflux 
EMT  Epithelial to mesenchymal transition 
EPOS European Position Paper on Rhinosinusitis and Nasal Polyps 
ERD Erosive reflux disease 
FESS  Functional endoscopic sinus surgery 
GER Gastroesophageal reflux  
GERD Gastroesophageal reflux disease 
GerdQ Gastroesophageal reflux disease Questionnaire 
IgE Immunoglobulin E 
H. Pylori Helicobacter Pylori 
IL Interleukin 
LES Lower esophageal sphincter 
LPR Laryngopharyngeal reflux 
NERD Non erosive reflux disease 
NLR  NOD-like receptor 




NOD Nucleotide-binding oligomerization domain 
NP Nasal polyps 
NSAIDs nonsteroidal anti-inflammatory drugs 
OME Otitis media with effusions 
OSAS  Obstructive sleep apnea syndrome 
PCD Primary ciliary dyskinesia 
PND Post nasal drip syndrome 
PPI Proton pump inhibitor 
RDQ Reflux Disease Questionnaire 
SAP Symptom association probability 
SI Symptom index 
SNOT-20 20-item Sino-Nasal Outcome Test 
SNOT-22 22-item Sino-Nasal Outcome Test 
SCUAD Severe chronic upper airway disease 
Th1 T helper cell type 1 
Th2 T helper cell type 2 
TLESR Transient LES Relaxation 
UES Upper esophageal sphincter 






Chronic Rhino Sinusitis (CRS) is one of the most prevalent chronic disorders in 
industrialized countries. The disease has a major negative impact on quality of life, 
social and professional capacity as well as health in general. The etiology is 
multifactorial and partly unknown. As patients may have symptoms inadequately 
controlled, despite treatment as recommended by internationally validated guidelines, 
there is a need to understand more of this disease. It has been discussed for decades if 
gastroesophageal reflux (GER) may have a role in the pathogenesis of CRS in some 
patients. 
Objectives:  
The main aim of this research was to obtain a better understanding of the role of GER 
in CRS and to get a final answer to the question: Is there an association between 
GERD and CRS? 
 Investigating the sino- and nasal-quality of life in patients with 
gastroesophageal reflux disease (GERD) compared to a control population. 
 Assessing the occurrence of reflux in CRS-patients with the 24-hour 
multichannel intraluminal impedance pH-monitoring.  
 Evaluating the presence and level of pepsin in saliva and nasal secretions, in 
CRS-patients compared to age and gender matched healthy controls.   
Methods:  
Three controlled studies were carried out, one on GERD-patients and two on CRS-
patients.  
 We used the 20-item Sino-Nasal Outcome Test in GERD-patients and a 




 We performed 24-hour esophageal multichannel impedance pH-monitoring in 
CRS-patients and compared the results with data from a European trial on 
healthy subjects.  
 We used the Peptest®, an assay for detection of pepsin, to evaluate the 
findings of pepsin in CRS-patients and an age and gender matched group of 
healthy controls.  
Results: 
 Patients with GERD had a reduced nose- and sinus-related quality of life 
compared to a control group based on having a significantly higher total 
SNOT-20 score. Accordingly, this study indicates that there may be an 
association between GERD and CRS. 
 CRS-patients had significantly higher incidence of gastroesophageal reflux 
compared with asymptomatic controls as measured with 24-h esophageal 
multichannel impedance-pH monitoring. 
 As measured by the Peptest, we did not find more pepsin in saliva or nasal 
secretions in CRS-patients than in healthy controls, nor in those with high 
GerdQ scores or verified proximal reflux. We measured high concentrations of 
pepsin in both patients and healthy controls. This indicates a limited validity of 
the Peptest as screening tool for GER in CRS.  
Conclusions: 
The reduced sino- nasal quality of life in GERD-patients compared to healthy 
controls indicates a possible link between GERD and CRS.  
More reflux in CRS-patients compared to asymptomatic controls and the proximal 
extent of refluxate further indicates a link.  
High concentrations of pepsin in nasal secretion and saliva in both CRS-patients and 
healthy controls, as measured with Peptest, indicates a limited validity of the test for 




by the absent correlation between Peptest and proximal reflux as measured with 24-
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The role of gastroesophageal reflux (GER) in chronic rhinosinusitis (CRS) has been a 
controversy for decades. According to the Montréal definition and classification of 
gastroesophageal reflux disease (GERD) there is a connection between GERD and 
the airways and a possible connection between GERD and CRS (1). Both GERD and 
CRS are common diseases, and coexistence by chance is to be expected. In the 
European Position Paper on Rhinosinusitis and Nasal Polyps from 2012 (EPOS2012), 
it is concluded that more research is needed to conclude about GERD as a possible 
causative role in CRS (2).  
4.1 The healthy sino-nasal system 
 Anatomy 
The first description of the paranasal sinuses is credited Galen (130-210 AD) nearly 
two millennia ago with reference to Galen`s “De usu partium” were they are 
described as the “Porosity of the scull”. It was Leonardo Da Vinci (1452-1519) who 
gave the first detailed description of the anatomy of the paranasal sinuses with 
illustrations containing descriptions of both frontal and maxillary sinuses (3). 
The paranasal sinuses consist of the frontal, maxillary, ethmoid and sphenoid sinuses 





Figure 1. The nose and the paranasal sinuses. The frontal sinuses above the 
eyes, maxillary sinuses below the eyes, ethmoid between the eyes and 
sphenoid sinuses behind the eyes in the midline. 
The epithelium of the sino-nasal mucosa consists mostly of ciliated columnar cells 
(80%), but also mucus producing goblet cells and progenitor basal cells are present 
(5). 
 The function of the nose 
The nose is essential for human health, mainly related to respiration and olfaction. 
Respiration through the nose gives completely different condition for the lungs 
compared to the oral alternative. During nasal inspiration, the air is filtered, 
humidified, tempered and supplied with nitric oxide, enhancing normal lung function.  
 The mucociliary system 
The airway epithelium is covered by a two-layered liquid phase. The periciliary fluid 
(the sol phase) with low viscosity enabling the cilia to beat without resistance and the 
mucus layer (the gel face) with high viscosity that traps inhaled particles. This two-
layered liquid phase, together with the biphasic ciliary beating, plays an important 
role in the clearance of the mucosal surface of the nose and sinuses, called the 




pollutants, allergen and microbes etc., and thereby contributes to prevention of CRS 
and to proper flow of air (6, 7). 
 The function of the paranasal sinuses 
Why do we have paranasal sinuses? According to Negus in 1957, these air-filled 
spaces do not have any specific function. They are just evolutionary remnants. (8). 
However, in “Eighteen hundred years of controversy” regarding the function of the 
paranasal sinuses (9) tenable theories are identified and discussed. 
Resonance to the voice 
There is no consistent correlation between the size of the sinuses and resonance of the 
voice. Some animals with powerful voice have large sinuses, e.g. howling monkeys. 
On the other hand, lions with small sinuses have powerful voice and guinea pigs 
while giraffe with relatively quiet voice have large sinus cavities (10).  
Humidifying and warming inspired air  
The exchange of air in the sinuses during respiration has been suggested to contribute 
to both warming and humidifying of inspired air. However, as the volume of this are 
negligible several authors have doubted this theory. In this perspective, the size of the 
nasal turbinates is of much greater importance (10). 
Olfactory function 
It has been proposed that the paranasal sinuses are increasing the olfactory area. 
However, as they are lined by non-olfactory epithelium, this theory is probably false 
(10).   
Thermal insulation  
The role of the sinuses in providing thermal insulation to vital parts of the brain, has 
been suggested, but also dismissed. Eskimos and certain species of monkeys, living 
in cold climate, frequently lack frontal sinuses while they frequently are large in 




Protection against trauma 
It has been suggested that the sinuses may have a role in absorbing trauma and thus 
protect the cerebrum. However, as i.e. moose do not have large sinuses and do sustain 
high impact trauma without damaging sensory organs, this theory has flawed (10).   
Assisting growth 
A role of the frontal and maxillary sinuses in the growth and formation of the face, 
has been debated. However, as people having only a single frontal sinus, do not 
necessarily show asymmetric facial development for the theory is probably not valid 
(10).   
Reduce the weight of the head 
The theory that the air-filled sinuses are lightening the skull to maintain equipoise of 
the head seems unlikely. Calculations have shown that if the sinuses where filled with 
spongy bone, the weight of the head would only rise with one per cent (10). 
Mucus production 
An old theory saying that the physiological purpose of the sinuses is to produce 
mucus to moisten the nasal cavity is dismissed by the fact that the mucosa in the 
sinuses contain very few glands and the amount of mucus produced in the sinuses 
will not be significant (10). 
Production of nitric oxide (NO)  
Production NO takes place in both the paranasal sinuses and the nasal cavity. Thus, 
the sinuses are aiding nasal cavity specific immune defense as NO is both virocide 
and bactericide. NO can upregulate the ciliary beat frequency and thus further support 
the unspecific mucosal defense both in the upper and lower airways (11). The nasal 
and paranasal NO production has an important role in ventilation perfusion as the 
vasodilation effect of NO is enhancing pulmonary oxygen uptake. In patients with 





Thus, currently, knowledge, it seems that the function of the sinuses simply is to 
improve the airway function through additive production of NO (Keir 2009). 
4.2 Rhinosinusitis 
Rhinosinusitis is defined as concurrent inflammation of the mucosal lining the nose 
and paranasal sinuses. Depending on the frequency and duration, it is defined as acute 
or chronic (2). 
According to EPOS2012, rhinosinusitis is characterized by two or more symptoms, 
one of which should be nasal blockage/ obstruction/ congestion or nasal discharge 
(anterior/ posterior nasal drip). There may also be facial pain/ pressure and reduction 
or loss of smell. These symptoms should be combined with objective signs of disease 
found by CT scan or endoscopy with/ or without nasal polyps, mucopurulent 
discharge and/ or mucosal edema of the ostiomeatal complex.  
By scoring the answer to the question: “How troublesome are your symptoms of 
rhinosinusitis?” on a 100 mm VAS scale, the disease can be graded as; mild (0-30), 
moderate (31-70) or severe (71-100). A VAS >5, indicates a level of disease affecting 
the patient´s quality of life (2). 
 Acute rhinosinusitis (ARS) 
Definition  
Acute rhinosinusitis (ARS) in adults is defined as rhinosinusitis, lasting for less than 
12 weeks with complete resolution of symptoms and symptom free intervals if the 
disease is recurrent. 
According to EPOS 2012, ARS also includes common cold, a mild, usually self-
limited, upper respiratory illness. Common cold (acute viral rhinosinusitis) is defined 
to last for less than ten day. Although benign in character, it is a huge economic 
burden on society due to its commonness, frequent health care visits and absence 




increase of symptoms after five days or the symptoms are persistent after ten days but 
lasts for less than 12 weeks. 
Epidemiology 
ARS is a common disease with a prevalence varying from six to 15 % in different 
studies depending on study parameters (2). The condition is primarily handled in 
primary care. 
Pathophysiology 
As ARS is most frequently caused by viruses, and viral infection increase the 
bacterial adhesion to the mucosa, a very small subgroup of acute post-viral 
rhinosinusitis has a bacterial supra infection. ARS is normally appearing in this order: 
viral (common cold), post-viral and bacterial acute rhinosinusitis (ABRS). Only 0.5-
2.0 % of patients with viral ARS develop an acute bacterial infection secondarily. In 
ABRS, there will normally be fever, elevated CRP, severe local pain (unilateral 
predominance), worsening of sickness after an initial milder period and/ or purulent 
nasal secretion with unilateral predominance of discolored discharge (2). 
The most common viruses isolated in adults with ARS are rhinovirus. Coronavirus is 
another frequently occurring pathogenic factor. (13). The most common bacteria in 
ABRS are Staphylococcus pneumonia, Haemophilus influenza, Moraxella catarrhalis 
and Staphylococcus aureus.  
There may be a pathophysiological link between allergic rhinitis (AR) and ARS (14), 
possibly because of changes in ciliary motility (2). A swelling of the mucosa in the 
nose and sinuses with reduced exchange of gases between the two compartments may 
add to this.  Cigarette smoking has been suspected to predispose for ARS through the 
same mechanisms, but there is a lack of evidence for such a connection. However, 
cigarette smoke has been shown to release inflammatory mediators and alter ciliary 




Anatomical factors that theoretically could worsen the sino-nasal airflow like septal 
deviation, Haller cells, concha bullosa, choanal atresia, nasal polyps and hypoplasia 
of sinuses are more frequent in patients with ARS than in controls (2). 
Treatment 
Main treatment for most patients with ARS is nasal saline irrigation, nasal 
decongestants and topical steroids. As ABRS is rear compared to ARS, antibiotics are 
rarely indicated. In spite of this knowledge, antibiotics are frequently used on these 
patients both by specialists and by GPs. As increasing bacterial resistance and 
increasing use of antibiotics are major health problems, it is a paradox that the use of 
antibiotics in this group of patients is huge, a trend that definitely should be changed. 
Oral corticosteroids are normally not indicated (2). 
A Norwegian group has made a trial on Chloramphenicol eye drops on ARS and 
found it to be more effective compared to systemic antibiotics (16). 
Intranasal corticosteroids may improve ARS and are recommended, twice daily (17). 
Oral corticosteroids are normally not indicated (2). 
Nasal decongestants quickly open a stuffed nose, but it must be used with care due to 
high risk of adverse mucosal congestion if used for more than seven-ten days (2). 
Nasal decongestants combined with dexpanthenol has improved the efficacy of 
symptom relief in ARS (18). 
Phenylpropanolamine, a systemic mucosal decongestant, is prescribed by some 
family doctors, but rarely by specialists. The risk of side effects, such as dry mouth, 
neurological manifestations and possible a risk of cerebral hemorrhage, must be 
considered (19).  
External or internal nasal dilators may mechanically open the nasal vestibulum and 




 Chronic rhinosinusitis (CRS) 
Definition 
CRS is rhinosinusitis lasting for at least 12 weeks.   
Two phenotypes are defined; chronic rhinosinusitis with nasal polyps (CRSwNP) and 
chronic rhinosinusitis sine nasal polyps (CRSsNP). 
Epidemiology 
Chronic Rhino Sinusitis (CRS) is one of the most prevalent chronic disorders in 
industrialized countries today with major negative impact on quality of life, social 
and professional capacity as well as health in general (21).  
As a global agreement on the definition of CRS is lacking, reliable figures of the 
prevalence do not exist. However, it is estimated that CRS affects 15.5 % of the total 
population of United States (22). This makes CRS the second most prevalent among 
chronic diseases (2). The prevalence of CRS in urban population in Europa is 
between 5-15% (21) and approximately 12 % of Americans below 45 years have 
CRS (23, 24). Lange et al found the prevalence of CRS to be 9 % all over and up to 4 
% affected by sino-nasal polyps (25). 
The diagnosis of CRS cannot be determined by symptoms alone. It requires an 
investigation by specialist with CT scan or nasal endoscopy. Hence, it is likely that 
the diagnosis is underscored. Some epidemiological studies are based on symptom 
questionnaires only, and thus might be of limited reliability, difficult to assess and 
can give an overestimation (26). However, using the EPOS definition for 
questionnaires in epidemiological studies has a high reproducibility and a good 
correlation with endoscopic findings (27). 
Severe Chronic Upper Airway Disease (SCUAD) 
SCUAD is the term defining those patients with chronic upper airway inflammation 
and symptoms inadequately controlled despite treatment according to internationally 




rhinitis, occupational rhinitis, aspirin exacerbated diseases and recalcitrant CRS. 
Comorbidity are common in these patients and might increase the severity.  
SCUAD seems to be an underestimated medical problem, and there are gaps in 
knowledge of the disease and underlying mechanisms. However, it is stated that 
patients suffering from SCUAD should be handled with special attention because of 
risk factors, severity and possible novel treatment alternatives (Bousquet, Bachert et 
al. 2009) (Prokopakis, Vlastos et al. 2014).  
It is a hypothesis that these patients with severe disease in spite of guideline-driven 
treatment could share a common underlying pathophysiology. More research is 
needed in understanding these patients and optimize the treatment (28).  
CRS-patients as a group has impaired quality of life (29), and patients with SCUAD 
are assumed to suffer most. 
Pathophysiology 
CRS can be divided in subtypes, with pathological, etiological and clinical findings in 
common. The two phenotypes CRSwNP and CRSsNP are recent examples of such. 
Classifications based on underlying pathophysiological mechanisms, endotype 
classification, may open up for better understanding of multifactorial characteristics 
of the disease (30).  
Several contributing factors to CRS have been proposed: 
Bacteria 
Bacteria have been considered being a part of the pathogenesis in CRS in some 
patients, but their role is still rather unclear. ARS as initiator of CRS is a speculation. 
Bacteria in biofilm are believed to play a role in recurrent exacerbations (2).  
Biofilms 
Biofilm is an aggregation of micro-organisms, often bacteria, on a surface, covered 
by a slimy matrix (31). The extracellular matrix, produced by the micro-organisms, 




adherence between bacteria and to the surface of biological or non-biological material 
(32). This structure is protecting the bacteria from the surroundings, making them 
more resistant to i.e. antibiotics and the immune system. The biofilm is useful or 
harmful depending on where it is and what bacteria it contains. In human diseases, 
especially chronic infections, biofilm can complicate treatment, and as much as 80 % 
of chronic infections may be caused by biofilms (33). 
The establishment and cycle of biofilm may be described in five steps: 
 Bacteria settle reversibly on a surface 
 The binding to the surface becomes irreversible through production of 
polysaccharides  
 Extracellular polymeric substances surround the bacteria  
 The colony of bacteria is maturing as it increases in size and canals for 
communication are established in the matrix 
 As the biofilm reaches a “critical mass” where parts will have insufficient 
nutrition, parts of the biofilm will detach and might start a new biofilm (33). 
 
The presence of bacterial biofilm is reported in sino-nasal mucosa. As it is present in 
a high proportion of CRS-patients (32) it is suspected to be involved in pathogenesis 
of CRS in some patients. The biofilm in CRS is adding more inflammation and can 
damage the mucociliary system (6). The containing microorganisms are more 
resistant to antibiotics, and biofilm indicate a poorer prognosis. Staphylococcus 
aureus seem to be the dominant bacteria in biofilms in CRS, and the one associated 
with inadequate effects of medical and surgical treatment. More rarely Pseudomonas 
aeruginosa biofilm is present, and further reduces the potential for successful 
treatment (34). 
There may be an underlying mucosal deficit predisposing Staphylococcus Aureus to 




associated with high number of immune cells and a potential role in the pathogenesis 
of CRS (36).  
Viruses  
It has been hypothesized that viruses may be involved in the pathogenesis of CRS by 
being a source of chronic inflammation, but the evidence is scant, but viruses may 
trigger the first inflammatory process that pre-dispose for CRS and contribute to 
acute exacerbations of the disease (2, 37). 
Fungi 
Once, there was a theory that excessive immunological response to airborne fungi 
was the main pathological mechanism of CRS, the “Fungal Hypothesis of CRS”. This 
theory has later been more or less abandoned, as it is not supported by scientific 
investigations (2). But still, there are associations between fungi and CRS, probably 
due to local immunological or allergic reactions (38).  
Mucociliary dysfunction 
Primary ciliary dysfunction 
Primary ciliary dysfunction (PCD), including Kartagener`s disease, is a rare condition 
caused by more or less impaired ciliary motility due to more or less lacking dynein 
arms. The disease is an autosomal recessive genetic disorder and the diagnosis is 
based on electron microscopic investigations of mucosal specimens. CRS is common 
when there is a ciliary malfunction with negative impact on mucus transportation (6). 
Secondary ciliary dysfunction 
Secondary ciliary defect is caused by a variety of pathogens including viruses and 
bacteria (6).  
Cystic fibrosis (CF) may be regarded as a secondary ciliary dysfunction. Defect 
chloride channels in the cellular membranes and impaired salt balance in the 
respiratory secretions makes the latter viscous and difficult to transport. This creates a 





Nasal challenge with allergens may induce inflammation in the nose and the sinuses 
in patients with allergic rhinitis (AR). Besides, some patients with severe perennial 
AR may fulfil the diagnostic criteria for CRS, and the prevalence of both conditions 
is correspondingly increasing. However, AR has not been established as a 
predisposing factor for CRS (28).    
Aspirin (ASA)-exacerbated respiratory disease (AERD) 
There is a group of patients with CRS, many of them even suffering from asthma, 
that experience exacerbation of their diseases when they are exposed to aspirin. Many 
of them are inadequately controlled and categorized as SCUAD (26). Eosinophilic 
mucosal inflammation and nasal polyps characterize CRS with AERD. Aspirin and 
other NSAIDs exacerbate the condition, but the disease persists without exposure to 
NSAIDs. AERD occurs in 5-10 % of CRS-patients However, in CRSwNP it occurs in 
15%-40%. The role of aspirin as a precipitating factor is still unclear as reliable 
diagnostic tests for aspirin hypersensitivity are not available. Desensitization to 
aspirin is offered at some clinics, but the effect is disputed, and there is no consensus 
about treatment protocols. Due to high incidence of cross-sensitivity, all non-steroidal 
anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme might cause 
this kind of inflammation due to increase in leukotriene production and decrease in 
prostaglandin production (39). 
Anatomical factors 
There are anatomical variations that may contribute to the development of CRS due 
to narrowing of spaces in nose and sinuses. These are nasal septum deviation, concha 
bullosa and displaced processus uncinatus. However, studies do not conclude about 
the pathogenic role of these variations in CRS (2).  
Genetic factors 






Pregnancy rhinitis with nasal congestion is common during pregnancy, affecting as 
many as one in five pregnant women (40). Less is known about the association to 
CRS (2).  
Environmental 
Exposure to environmental toxins/ irritants like tobacco smoke and air pollutants, 
diesel exhaust in particular, promote epithelial damage and airway inflammation. A 
causal relationship between cigarette smoke and lower airways has long been 
established, but relationship to disorders in the upper airways has not been 
completely understood. However, the incidence of CRS is increased among smokers, 
probably due to negative impact on the mucociliary system (15). Smokers also 
respond less favorably to surgical measures against CRS (41). 
The correlation between air pollutants and CRS is best seen in CRSsNP (42).  
Occupational 
As there normally is long latency between occupational exposure and symptoms from 
the airways, a correlation might be difficult to understand and detect. When the 
inflammation and disease is established, it is often chronic. Though reducing 
occupational exposure, the symptoms often persist. Absence from work combined 
with reduced symptoms may indicate an occupational relationship such as in baker’s 
rhinitis (43). Baker’s rhinitis is well documented, but data on baker’s CRS is sparse. 
Immunodeficiency 
CRS is more common in patients with an immunodeficiency compared to others. This 
is specifically seen in IgA deficiency disorders and is correlated to low of count of 
CD4 positive cells as in AIDS (2). 
Immunological 
Understanding the immunological mechanisms behind CRS is improving. T helper 
cells are regulating immunological responses resulting in predominantly neutrophilic 




are slightly more frequent in CRSsNP than in CRSwNP and named non-type 2 
immune response (30). Natural T helper cell type 2 (TH2) with eosinophilia are 
dominant in CRSwNP (44) and these type-2 immunological reactions in the mucosa 
have led to classification of the disease into groups according to the underlying type-
2 immune response: Cytokine-based inflammations, eosinophil-based inflammation, 
IgE-based inflammation and cysteinyl leukotriene-based inflammation. 
Differentiation based on type of cytokines may currently be most useful in 
endotyping as there may be opportunities for cytokine specific treatment (30).  
Interleukin 5 (IL-5), a type 2 cytokine, is a key mediator in eosinophil activation that 
has long been associated with allergic diseases and has been a target in treatment of 
allergic asthma. Now it seems that IL-5 also is a key factor in the pathogenesis of 
CRS and there are ongoing studies on treatment of CRS targeting IL-5 (45).  
Staphylococcus Aureus plays a role in the development of CRS possibly by inducing 
superantigens and colonization in middle meatus. There is an increased prevalence of 
intranasal colonization of S. Aureus in CRSwNP, up to 87% compared to up to 33% 
in healthy controls (46).  
Staphylococcal enterotoxins (SE) are stimulating release of cytokines, such as IL-5. 
SE induced inflammation is present in large subgroups of CRSwNP (47). 
Three endotypes of inflammation are defined: Non-type 2, moderate type-2 and 
severe type-2 inflammation. Non-type 2 is typically found in CRSsNP, having a low 
risk of asthma and a low risk of recurrence, opposite to severe type-2 being involved 
in CRSwNP including high risk of asthma and a high risk of disease recurrence. 
Serum biomarkers, distinguishing between non-type 2 and type 2 CRSwNP are 
identified (30) with potential therapeutically implications in the future. 
A Swedish group has investigated the presence of NOD-like receptors (NLR) that are 
capable of trigging an immune response. They found higher density of NLR in nasal 




the level was normalized. Thus, they suggested that NLR might have a role in 
CRSwNP (48). 
Epithelial-to-mesenchymal transition (EMT) 
The molecular mechanism behind polypogenesis has not been fully understood, but 
resent studies suggest that a hypoxia-induced EMT may be an underlying mechanism. 
EMT is a biologic process in epithelium enabling the epithelium to assume a 
mesenchymal cell phenotype with degradation of underlying basement membrane, 
giving it new properties with an enhanced migratory capacity and invasiveness. When 
this disruption of normal barrier function occurs, there may be a stimulation of further 
inflammation with mucosal hyperplasia and subsequent polypogenesis.  
Surgical intervention prevents the recurrence of nasal polyposis by allowing re-
oxygenation. Hence, this supports that hypoxia has a critical role in the disorder. 
EMT correlates to severe CRS (49-51).  
GERD 
See chapter 4.5.8. 
Diagnostic methods in CRS 
According to EPOS2012, the diagnosis of CRS should be based on anamnesis, 
clinical examination and imaging.  
Symptoms/ Questionnaires 
The patients should be evaluated for nasal congestion, anterior and/ or posterior nasal 
drip, facial pain/ pressure and reduction/ loss of smell and taste. 
Among questionnaires available for symptom evaluation are; SNOT-20 (52), SNOT-
22 (53) and the VAS-CRS (2). 
Endoscopy 
Anterior rhinoscopy and endoscopy for investigation of the nasal cavity and is 




nose, the mucosal characteristics, and assessment of the middle meatus and 
ostiomeatal complex regarding discharge and polyps (4).  
CT-scan 
The Lund Mackay score is a widely used scoring system for CT-staging of CRS. The 
paranasal sinuses (frontal sinus, anterior ethmoidal cells, posterior ethmoidal cells, 
maxillary sinus, sphenoid sinuses) is scored, each side separately, according to; no 
abnormality, partial opacification or complete opacification (0,1 or 2 points). The 
ostiomeatal complex is scored according to; open, partly obstructed or obstructed (0.1 
or 2 points). The total score will then be between 0 and (Table 1) (54). 
Table 1. The Lund-Mackay scoring system for CT of the sinuses 
Sinus system Right Left  
Maxillary 0-2 0-2  
Anterior ethmoidal 0-2 0-2  
Posterior ethmoidal 0-2 0-2  
Sphenoidal 0-2 0-2  
Frontal 0-2 0-2  
Ostiomeatal complex 0-2 0-2  
Total Score 0-12 0-12 0-24 
Each sinus group is scored between 0 and 2 (0: represents no abnormality, 1: 
partial opacification and 2: total opacification) and ostiomeatal complex 
scored between 0 and 2 (0: open, 1 partly obstructed and 2 obstructed). 
The Lund-Mackay Staging System was developed to facilitate decisions about 
treatment of CRS. Originally, it included symptom scores, endoscopic scores and 
radiologic staging, but it is the radiologic staging that has become widely used (55). 
Treatment 
There are different therapeutic approaches to CRS due to different phenotypes and 




treatment and endotyping may in the future give more opportunities for more 
individually targeted treatment.  
The treatment of choice can be pharmacological or surgical or a combination of the 
two, depending on the etiology and severity of the disease. A combined medical and 
surgical approach is frequently used, but despite maximum effort, there are many 
patients without cure or symptom relief. 
The main objective of medical treatment is to reduce inflammation.  
The main objective of surgical treatment is to open narrow spaces, improve sino-
nasal communication and to remove pathological tissue. 
Medical treatment 
Glucocorticosteroids 
Glucocorticoids, administrated locally or systemically, reduce airway eosinophil 
infiltration through activation of intracellular glucocorticoid receptors. 
The efficacy of steroids is highest in the endotypes with inflammation type 2 (mainly 
cytokine based), i.e. CRSwNP. However, CRS-patients of other endotypes may also 
benefit from steroids. 
Intranasal corticosteroids are the preferred initial treatment for both CRSwNP and 
CRSsNP. In the former, drops may have superior effect on nasal volume and sense of 
smell compared to the spray due to higher steroid concentration and accessibility to 
the middle meatus and thus reduce the need for surgery (56). The application 
technique of the spray appears to be important for its effectiveness. The 
recommended technique is: blow the nose, shake the corticosteroid nasal spray bottle, 
bend the head forward, hold the spray bottle in the opposite hand to the nostril, place 
the tip of the spray bottle just inside the nostril and spray while breathing normally. 
Do not sniff while spraying as this may cause the medication to pass straight through 




Studies on systemic steroids in CRSsNP are limited, but in CRSwNP, there are beneficial 
effects. The risk of systemic side effects limits the indication to severe cases for short-term 
use (30). 
Saline Irrigation/ Douching 
Nasal irrigation with isotonic or hypertonic saline solution is recommended in CRS. 
Xylitol irrigation has, in some studies, given better improvement of symptoms as 
compared to saline irrigation alone (58). 
Long-term antibiotics 
Long-term treatment of CRS-patients with macrolide, seems to act primarily through 
immune-modulation rather than anti-microbial mechanisms. There are diverging 
results of studies, but patients with normal serum IgE and CRSsNP are more likely 
have an effect of 12 weeks on macrolides than atopics and those with polyps. The 
option should be reserved for those refractive to other alternatives (59). In CRSwNP, 
the documentation of beneficial effect is lower, but Doxycycline has shown 
promising result in some studies (60). The risk of bacterial resistance must definitely 
be kept in mind when considering this alternative.   
Proton Pump Inhibitor (PPI) 
According to EPOS2012, there is not documentation supporting a general 
recommendation for PPI in treating CRS in adults (2). Further, it has been stated that 
PPI is not effective in treating extraesophageal reflux if the reflux is nonacidic or 
nonacidic components are causing the problem (61). There appears to be a subgroup 
of asthmatics who benefit from PPI without having classical symptoms of GERD 
(62). Studies on treating laryngopharyngeal reflux (LPR) with PPI have shown 
improvement of nasal symptom (63). Generally, with PPI for extraesophageal reflux 
it takes high doses for a long period of time to have an effect. A double-blind trial on 
patients with both LPR and CRS with 20 mg Omeprazole daily for eight weeks, 




Aspirin desensitization  
Aspirin desensitization is not recommended as a routine treatment due to lack of 
evidence and risk of adverse reactions (39). 
Biologicals 
A trial with anti-IgE on CRSwNP, and comorbid asthma, reduced nasal symptoms, 
reduced nasal polyps, reduced Lund-Mackay scores and reduced the need for surgical 
and traditional medical treatment (65).  
Recently, Mepolizumab, an interleukin inhibitor previously used in severe 
eosinophilic asthma reduced size of nasal polyps, reduced nasal symptoms and 
reduced need of surgery in patients with severe CRSwNP (45).  
Current data after phase one and two studies of biologics on CRSwNP corresponds to 
maximum effect of short-term oral glucocorticosteroids treatment. Unlike the effect 
of corticosteroids, the effect maintained for a long period. Symptom relief and 
increasing quality of life came along with polyp reduction. As type 2 targeting 
biologics may be particularly efficient in type 2 CRSwNP, these patients should be 
identified (30).  
Surgery 
Though there is a lack of high-level evidence, functional endoscopic sinus surgery 
(FESS) is regarded as safe and effective in treatment of CRS when medical treatment 
has failed and it is justified by the patient’s symptoms (2). Surgery is more effective 
on nasal congestion and facial pain than on loss of smell and nasal secretion.  
Long-term outcome of surgery is better in CRSsNP compared to CRSwNP, were the 
polyps frequently reoccur. The surgery can have different approaches depending on 
the disease, from mucosa sparing surgery in mild cases of CRSsNP to extended 




4.3 The Upper Gastrointestinal System in Health 
 The Esophagus 
The esophagus is a tubular organ consisting of longitudinal and circular muscle 
extending from the upper esophageal sphincter (UES) to the lower sphincter (LES). 
The sphincters are muscular rings giving narrow parts proximally and distally. 
Additionally, there is a narrow section at the level of the aortic arch (66) (Figure 2).   
  
Striated muscle fibers dominate the upper third of the tube, while there is smooth 
muscle in the distal two thirds. Stratified squamous epithelium, innervated by nerve 
fibers going superficially, covers the lumen and makes the esophagus more sensible 
to acid compared to the stomach having more protection against acid. There are a few 
Figure 2. The esophagus with 
three narrow parts; lower 
esophageal sphincter (LES), upper 
esophageal sphincter (UES) and 




mucus-secreting glands in distal part of the esophagus. The esophagus has a rich 
blood supply. 
Due to peristalsis in the esophagus and relaxation of sphincters, there is active 
transport of food and drink to the stomach, while retro-peristalsis will for allow 
vomiting.  
Ructus, defined as containing only air, is a physiological process to prevent the body 
from being filled up with air, but there can be a hard balance between the 
physiological reflux of air and pathological liquid reflux. As transport mechanisms 
will allow ructus to evacuate air, mainly after meals, an imbalance in this mechanism 
may cause mucosal damage (66).  
 Stomach 
The stomach consists of two parts, the corpus/ fundus and the antrum. The production 
of acid from parietal cells and pepsinogen from chief cells take place in the corpus/ 
fundus part where the food is stored and mixed with secretions.  
In the antrum, the food is kneaded into smaller particles before entering the 
duodenum.  
Enterochromaffin-like cells, stimulated by gastrin, synthesize and secrete histamine, 
which stimulates production of acid and pepsin prior to food entering the stomach. 
The process may be elicited purely by the sight or taste of food. A vagus-mediated 
relaxation provides an extension of the stomach volume, and thus prevents the 
pressure in the stomach from rising higher than the pressure in LES when food enters. 
Bile and pancreatic enzymes may enter the stomach retrograde. 
 Pepsin 
The name of the proteolytic enzyme pepsin originates from the Greek word for 
digestion. It is responsible for the first breakdown of proteins in the food to peptides 




Figure 3. The enzyme pepsin. 
gastric juice (67). It originates from pepsinogen, secreted from the chief cells in the 
stomach, and is converted to pepsin in the acidic environment in the stomach. Pepsin 
is highly sensitive to acid and most harmful in its acidic state at pH 2-3. However, it 
can be active and cause injury up to pH 6.5. Though not being active when pH is 
between six and eight, it is not de-naturalized, and can be reactivated. This implies 
that when pH in refluxate is above 4, and thus not detected by pH monitoring, there 
can still be active pepsin in the refluxate. Besides, theoretically, inactive pepsin can 
be reactivated and become harmful by a decrease in pH due to acid drinking or later 
acidic reflux events (68). 
A mucous-producing lining is protecting the stomach from auto-digestion from 
pepsin. In contrast, neither the squamous tissue lining the esophagus, nor the surface 
of the airways do have this protective layer. This gives sensitivity to refluxate, and a 
risk of injury of epithelia of both esophagus and epithelium of the airways. The nasal 
mucosa may have even less protective capacity against the refluxate and thus, is even 
more sensitive to its injurious influence. 
In extraesophageal tissue, pepsin may be endocytosed into epithelial cells and has 
been shown to give internal cell derangements (69). 
Pepsin is a group of pepsin molecules with small differences in molecular 





Pepsin is actually a group of pepsin molecules, isoenzymes with small differences in 
molecular characteristics. As the human pepsin A, is produced in the stomach only, 
and there is no production of pepsin A elsewhere in the body, findings of this in the 
esophagus, mouth or respiratory tract, is a diagnostic biomarker of gastroesophageal 
gastric reflux. Different isoenzymes of pepsin A can be found in the gastric juice, and 
normally pepsin 3a, 3b and 3c, comprises up to 80% of the total enzymes secreted 
(70). The problem with using pepsin assays in the diagnostic workup of reflux has 
been lack of specificity to pepsin A of the available assays. Other isoforms of pepsin 
are also produced in lungs, pancreas (71). 
 Antireflux mechanisms 
These are the mechanisms protecting against reflux of gastric content, and which may 
explain why it is not even more frequent, and harmful.  
Saliva and mucus production 
A few mucus-producing glands in the distal few centimeters are responsible for a 
very limited mucus production in the esophagus. This tiny mucus production in 
combination with swallowed saliva may neutralize acid reflux. Furthermore, there are 
mechanisms inducing increased saliva production in response to reflux, giving even 
more neutralization. The symptom of hyper-salivation is called “water brash” (72, 
73). As tobacco smoking decreases the salivary bicarbonate production, smoking will 
reduce this protective capacity (74). 
Peristalsis and swallowing 
The movements in the esophagus induced by swallowing is primary peristalsis. 
Swallowing will work against reflux, starting at the top, and thereby move refluxate 
distally in the esophagus and drain it back into the stomach. So-called secondary 
peristalsis can start more distally than during swallowing and drains food from the 
esophagus and refluxate towards the stomach. Such secondary peristaltic movements 
are reflex mechanisms initiated by large amounts of refluxate expanding the 
esophagus. Hence, these mechanisms are working e.g. if having reflux when lying 




Lower sphincter function 
The muscular tone in LES is an important anti-reflux mechanism. When the resting 
pressure in the LES is higher than in the stomach, it will protect against reflux. 
Normally, the smooth muscle of LES will be a part of the gastroesophageal junction, 
as the smooth muscle of LES will be an intrinsic factor and the surrounding 
diaphragm, will work as an external sphincter (66).   
Upper sphincter function 
The upper sphincter (UES) is also a part of the antireflux system, but the knowledge 
of its function is more diffuse. It appears to be regulated together with the LES, 
allowing ructus to be evacuated. When the UES is closed, as it normally is, it 
prevents reflux to the airways (66). 
Crus dexter of the diaphragm 
The only muscle of the diaphragm that is in direct contact with the wall of the 
esophagus, is named the crus dexter diaphragm (crural diaphragm) (Figure 5, chap 
4.4, page 44). Unlike the smooth muscle of LES, it is striated. Forming a loop at level 
of the LES, its contraction will protect against reflux when there is a higher pressure 
in stomach compared to LES. Respiration, cough or heavy lifting that increases the 
abdominal pressure are typical situations where this mechanism comes into action. 
Usually, there will be a simultaneous contraction of the diaphragm (75). 
His angle 
His angle is the name of the sharp angle between the stomach and the esophagus. 
When there is a distension in the stomach due to a meal, the distal esophagus will be 
squeezed by the stomach and support the LES in protecting the esophagus from 




4.4 Gastroesophageal reflux disease (GERD) 
Normally, there is a balance between injurious forces, the acidic refluxate with 
varying potency of damage, and defensive forces which include the sphincters, 
esophageal acid clearance and mucosal integrity, resulting in no injury or symptoms 
due to reflux of stomach contents (76). Gastroesophageal reflux (GER) may be a 
physiological and normal event occurring occasionally in all people, without 
symptoms or complications. In patients with GERD, this balance is disturbed. Several 
factors may be involved and, although poorly documented, a number of behavioral 
aspects such as smoking, heavy meals before bedtime, obesity and specific foods may 
affect this balance (76).  
The most common typical presentation of GERD is heartburn and regurgitation (77). 
Definition      
GERD is defined as a condition that develops when reflux of stomach contents causes 
troublesome symptoms and/ or complication. The purpose of this phrasing is that the 
diagnosis should include both patients with symptoms only and patients without 
symptoms but with complications, irrespective the technology used to achieve it. (1). 
Troublesome symptoms are normally defined as symptoms of reflux at least once 
weekly (78). 
The manifestations of disease are divided into esophageal and extra-esophageal 
syndromes (1) (Figure 4). 
Esophageal Syndrome 
The Montral definition and classification of GERD defines the esophageal 
syndromes, previously called the classical manifestations, as both symptomatic 
syndromes with typical symptoms of regurgitation and heartburn and syndromes with 
esophageal injury. The typical syndrome with esophageal injury is reflux esophagitis, 
but may also include reflux stricture, Barrett`s esophagus and adenocarcinoma 





The former is further divided into erosive reflux disease (ERD) or non-erosive 
esophageal reflux disease (NERD) depending on whether there is visible damage to 
the esophageal mucosa or not. 
 
The Montréal Definition and Classification of 
GERD 
Figure 4. The subdivision of GERD according to The Montréal Definition and 
Classification of GERD (1). 
Extraesophageal Reflux (EER) 
Small episodes of EER may damage mucosa of the airways, but there can be numbers 
of acidic GER episodes in persons without the typical symptoms of GERD (79, 80). 
Gastric reflux entering the laryngopharynx has also been termed laryngopharyngeal 
reflux (LPR).  
Unlike the esophagus, extraesophageal tissue do not have the surface protection 
against refluxate. Further, the peristalsis of the esophagus will rapidly return 
refluxate, particularly after meals, to the stomach. Thus, the esophageal peristalsis 




does not have this protection, and an episode of reflux is likely to influence the 
surface for a longer period of time (69). It has also been suggested that EER is 
mediated by pepsin and that typical GERD is mediated by acid. This difference in 
pathophysiology might explain why PPPs fail to rapidly improve EER disease (69).  
Extraesophageal syndrome can occur concomitantly with esophageal syndrome or 
alone. As much as half of patients with EER, do not present with the typical 
symptoms of GERD (81), but extraesophageal symptoms alone. This may give a 
delay in both diagnosis and appropriate treatment.  
According to the Montréal definition and classification of GERD, the extra 
esophageal syndrome may be divided in two groups; the extraesophageal syndromes 
with an established connection to GERD and the extra-esophageal syndromes with only 
a proposed association. GERD has an established association to cough, laryngitis, 
asthma and dental erosions and a proposed association to pharyngitis, CRS, 
idiopathic pulmonary fibrosis and recurrent otitis media (Figure 4) (1). See chapter 
4.5 for further details. 
Epidemiology 
GERD is a common disease in western countries with a prevalence that may be as 
high as 20-40 % involving a spectrum of symptoms of some severity possibly related 
to reflux, typical symptoms of GERD and symptoms of EER (82). The prevalence 
may be increasing over time (83). The Norwegian HUNT study found increased 
prevalence of GERD between 1995-1997 and 2006-2009, symptomatic weekly 
GERD increased by 47% (84). 
When defined as at least weekly symptoms of heartburn and/ or acid regurgitation, 
the prevalence of GERD is reported to be 10-20 % in western countries, and in Asia 
less (85).  
There is a tendency of increasing prevalence with age, but the effect of both age and 
gender is unclear (86, 87). There is a tendency that a genetic component predisposes. 




America compared to Europa (78). Furthermore, the Norwegian HUNT study shows 
more GERD among smokers (86). 
Mechanisms of reflux 
Hiatus hernia 
When having a hiatus hernia, the LES and crus dexter diaphragm is separated (Figure 
5). Thus, a contraction of the crural diaphragm will squeeze the bottom of the hiatus 
hernia, and not support the LES. After a meal, there will normally not be food in the 
hiatus hernia. However, when the intraabdominal pressure increases due to e.g. cough 
or heavy lifting, acid from the acid pocket in the hiatus hernia will easily reflux to the 
esophagus. In this situation, a contraction of diaphragm and crus dexter, will not give 
a protection. Due to these mechanisms, the hiatus hernia will predispose for reflux 
and GERD (88).
 
Figure 5. Hiatus hernia. The gastroesophageal junction and LES do not have the 





Transient LES Relaxation (TLESR) 
A transient relaxation of LES is a normal physiological event, mainly to allow 
ventilation of air and happens independently of swallowing of food. A CNS mediated 
vaso-vagal reflex stimulated by dilatation of the ventricle may be the mechanism. 
This happens typically postprandially but can occur whenever during a day. The 
TLESR lasts for 20-30 seconds and is most important in low-grade GERD. 
Hiatus hernia is associated with an increased incidence of TLESR (Figure 5).  
Abdominal Pressure 
When abdominal pressure exceeds the pressure in LES, the result can be reflux. Increased 
abdominal pressure will for example happen when coughing or making heavy lifting. 
Visceral obesity and external pressure on the stomach may further increase the risk. 
Low LES Pressure 
Reduced pressure in LES gives a risk of reflux as the abdominal pressure may exceed that in 
lower LES and thus allow ventricular content to pass. This also includes nightly reflux. 
A number of triggers have the potential of reducing the tension in LES. Food, medication 
and hormones are examples of such. Tobacco smoking is also lowering the sphincter 
pressure (87).  
Acid pocket 
Particularly after a meal, there will be an accumulation of acid in upper part of the 
stomach covering the food. This is called the acid pocket, often having a pH between 
1 and 2. The acid pocket is close to the esophagus, and as it is in a liquid state, it 
easily refluxes in to the esophagus resulting in very acidic refluxate.    
Impaired nervus vagus activity 
The vagal nerve is important for normal motoric activity in esophagus and ventricle 
(66) and there are speculations that an impaired nerve function can be a cause of 





Diagnostic methods in GERD 
Symptoms 
Heartburn and regurgitation are the most typical symptom of GERD and as 
troublesome symptoms meets the criteria for the diagnosis of GERD, questions about 
these symptoms could be diagnostic, and be a legitimate basis for a trial of medical 
therapy. However, studies have shown that physicians underestimate the importance 
of symptoms reported by patients, and they may overlap with functional dyspepsia 
(77). Hence, symptoms of reflux are best assessed with validated patient-reported 
outcome instruments.  
Questionnaires 
Structured questionnaires may reduce variability between physicians and between 
patients in interviews, and many questionnaires about GERD are available. Most of 
them were originally developed and validated for the monitoring of symptoms in 
treatment trials (77). 
Reflux Disease Questionnaire (RDQ) (89) and Gastro Esophageal Reflux Disease 
Questionnaire (GerdQ) (90) (91) are validated questionnaires used in diagnostic 
workup of GERD and in evaluating effect of treatment. GerdQ is derived from RDQ 
and is easier to use (92). A randomized clinical trial compared a GerdQ-based 
algorithm with an endoscopy-based approach for the diagnosis of GERD. They found 
that by using the GerdQ, the health care costs were reduced without loss in diagnostic 
efficacy. Using GerdQ for the diagnosis of GERD, with a cut-off level of eight in 
total score, gave a sensitivity of 65% and a specificity of 71% (90). 
All the symptom-based questionnaires rely on medical history with the presence or 
absence of typical symptoms and may not discover atypical cases with extra 
esophageal syndromes. As a large proportion of patients with EER, lack the typical 
symptoms of GERD with heartburn and dyspepsia (93), the questionnaires may not 
be useful in these cases as the sensitivity may be low.  




Thus, the patient´s self-reports about GERD must be treated with caution and 
recommended to be supplemented with objective measures, dependent of the severity 
of the disease.  
PPI test 
PPI test, treatment with PPI followed by evaluation of effect, has been used for 
diagnostic purposes for GERD. One approach has been to give PPI for four weeks 
and evaluate both the effect of initiating PPI and the effect of withdrawal. The effect 
on classical GERD symptoms appeared already after three days. The sensitivity in 
this study was good, more than 80% responders, but the specificity was low. Some 
responders did not fulfil the criteria for the diagnosis of GERD, and the response 
might be due to effect on functional dyspepsia (94). It is also found that symptom 
response to a two-week course of 40 mg esomeprazole does not add diagnostic 
precision (95).  
Generally, PPI tests are considered as unreliable for the diagnosis of GERD (77). 
Gastroscopy 
Upper Gastro-intestinal endoscopy has high specificity in diagnosing GERD (96). 
However, the sensitivity is low, as it will only include patients with visible 
esophageal lesions, missing the cases of non-erosive reflux disease (NERD). The 
findings on gastroscopy are classified according to the Los Angeles Classification of 
the esophagus (LA). This classification is grading the mucosal pathology in four 
groups from A to D. A is defined as one or more mucosal breaks less than five mm 
long and not extending between the tops of the mucosal folds, and D is defined as 
mucosal break involving at least 75% esophageal circumference (97). 
The presence of visible manifestation of esophageal pathology in classical GERD 
may be as low as 50% (77, 98) and even suspected to be lower, especially in EER.  
Manometry 
Manometry is standardly performed prior to pH and impedance pH-monitoring to 
plan the placement of the probe. The manometry will further evaluate the motility and 





Routine clinical pH measurement is performed with a pH sensor only in the distal 
esophagus, and it does not allow characterization of the proximal extent of the 
refluxate. 24-hour pH-recordings of the esophagus were for many years the gold 
standard in diagnostic workup of GERD. However, the technique does not allow 
registration of non-acid reflux, and the rate of false negative, but also false positive 
tests may be as high as 30% (99). Proximal esophageal and pharyngeal pH 
monitoring has been performed. However, the reproducibility is low, and it is not 
used routinely (100).  
The total number of reflux episodes and cumulative time when the esophagus is 
exposed to acidic refluxate are important indicators of the competence of the 
antireflux barrier (101). There is also a lack in utility of pH monitoring as non-acidic 
reflux and gas-reflux may not be detected by this technology. 
Esophageal impedance pH-monitoring 
Impedance monitoring of the esophagus is the latest diagnostic method for evaluating 
gastroesophageal reflux. Combined with pH measuring, it currently regarded as the 
diagnostic procedure of choice for the entity by many clinicians and investigators.  
It is the most sensitive method for detection and characterization of GER. Twenty-
four-hour multichannel intraluminal impedance pH-monitoring can detect both acid 
and non-acid reflux, as well as the number of events and their proximal extent (102, 
103).  
Intraluminal impedance monitoring allows detection of gastroesophageal reflux based 
on changes in resistance to electrical current flow between two electrodes, when a 




This system includes a portable data-logger with impedance-pH amplifiers, and a 
single use catheter. The catheter contains one or two pH-electrodes, often one at the 
tip (gastric) and always one positioned five cm above the LES. There are usually 
eight electrodes, typically positioned 2, 4, 6, 8, 10, 14, 16 and 18 cm above the LES 
giving the opportunity of measuring impedance at six different levels in the 




Figure 6. The impedance 
catheter with eight 
electrodes is positioned 2, 
4, 6, 8, 10, 14, 16 and 18 
cm above LES, giving the 
opportunity of measuring 





This allows for the evaluation of the distal and the proximal extent of reflux episodes. 
The amplifier delivers an AC voltage with a frequency between 1 and 2 kHz and 
measures variations in impedance measures in response to changes in luminal 
diameter. As air has low electrical conductivity, it will provoke rapid and pronounced 
rise in impedance in contrast to liquid, which will lower impedance. Dilation of a 
cavity with fluids will therefore reduce impedance. The change in impedance due to 
movement of liquid and air in the esophagus is the principle behind impedance 
monitoring (Figure 7a-7d). Segmentally, the resistance to an electric current due to 
detection of reflux of air and liquid. 
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Figure 7b. Impedance monitoring of distal 
reflux. Reflux in the distal esophagus gives high 
electrical conductivity between the electrodes 
and the impedance falls in the distal segment. 
Figure 7c. Impedance monitoring of 
esophagus when the refluxate has reached 
the proximal esophagus. Drop in impedance 
in the mid and upper esophagus indicates 
proximal liquid. 
Figure 7d. The impedance measuring in 
esophagus falls as liquid returns to the 
stomach. 
Figure 7a. Impedance monitoring of the empty 
esophagus. No liquid in esophagus gives low 
conductivity between electrodes and high 




Measuring pharyngeal reflux has been attempted in studies, but the investigational 
techniques are difficult in the presence of air and poorly reproducible. While 24-hour 
impedance pH-monitoring studies of esophagus have shown good reproducibility, 
both proximally and distally, the monitoring of impedance in upper airways is not 
reproducible (103, 104). 
The number of episodes detected in healthy subjects by impedance at all levels are 
relatively similar in different studies in Europe and USA (102-104). 
It has been debated to what extent automatic analysis is reliable and comparable to 
manual editing. A software program must be able to distinguish between impedance 
changes due to real reflux and changes due to non-reflux phenomena such as 
swallowing or artifacts of in intra-esophageal impedance. Software has improved 
over the years and currently performs well this (ref. by Albert Kramer at VCM 
Medical, The Netherlands, personal communication). 
A reflux episode may be defined as proximal when the event first is detected as distal 
reflux, the decline in impedance is >50% and must progress to at least one of the two 
proximal impedance segments. It is still necessary to confirm such a finding by visual 
control by a trained clinician or technician. In clinical practice, this may not be 
routine, but for research, this is mandatory, due to somewhat imprecise detection by 
commercially available software. 
Impedancemetry is used to calculate several parameters, including total number of 
reflux events, and the subgroups according to posture and pH. This is likely to be the 
best documented and reproducible variable that can be extracted from a 24-hour 
recording. Bolus exposure, defined as cumulative duration of decline in impedance to 
<50% of resting impedance, may be a less reproducible parameter.   
Detection of pepsin 
As diagnostic methods for GER, are either invasive, expensive or have low sensitivity 
and specificity, there has been a need for alternative approaches. Detection of pepsin 




Pepsin has been found in lungs, saliva, nose, sinuses, middle ear and exhaled breath 
condensate and this has been assumed to represent reflux of pepsin from the stomach. 
The utility though, of detection of pepsin as a diagnostic marker, is not established 
(67, 105). As pepsin actually is a family of isoenzymes, and the fact that different 
isoenzymes seem to have different characteristics and may even be produced at 
different location, it has been recommended to distinguish between the isoenzymes 
when testing. As available pepsin assays might not be specific for pepsin A, the 
isoenzyme found only in the stomach, there might be a limited validity of pepsin as a 
biomarker for gastric juice and hence for GERD when used on saliva (71).  
Different methods for pepsin detection exist.  
Peptest® (RD Biomed Ltd, Cottingham, UK) is a commercially available in-vitro 
diagnostic test for detection of pepsin in saliva. It is an enzyme immunoassay based 
on a lateral flow device technology. As Peptest is specific to pepsin A, the isoform 
that exclusively has been found in the stomach, there has been great expectations for 
the usefulness of the test. The sensitivity and specificity were said to be 88 and 87 % 
respectively (106). It has been claimed that the test lacks sensitivity for predicting 
pathologic reflux in children (107) and a recent meta-analysis suggested the 
sensitivity and specificity to be lower, 64% and 65% respectively (108). 
According to the manufacturer, pepsin analysis is to be performed on 1 ml saliva 
samples delivered by subjects immediately after symptoms, immediately after waking 
up in the morning and/ or one hour after meals, twice during the day. The glasses 
contain 0.5 ml µl of 0.01 M citric acid for conservation and the glasses are 
recommended to be stored in a refrigerator until analysis are performed within seven 
days (106). A control band on the device indicates correctly performed test and a 
second line indicates presence of pepsin in the sample. The lower limit for detection 
of pepsin with Peptest is 16 ng/ ml. The intensity of the detection line is proportional 
to the quantity of pepsin as read by the reader, LFDR101 (109). A study using 




the day and emphasized the importance of measuring pepsin in relation to the reflux 
symptoms (110).   
Mucosal impedance (MI) 
Esophageal mucosal impedance (MI) is a novel diagnostic method based on 
knowledge of dilated intracellular spaces (DIS) due to acidic-peptic injury to the 
apical surface of the mucosal epithelium because of reflux. It measures the chronicity 
of reflux by assessing changes in esophageal MI pattern independent of mucosal 
erosions and is highly specific for reflux. MI may be a tool for assessment of reflux in 
suspected EER in future (111). 
Treatment 
Treatment guidelines recommend life style interventions, over-the counter drugs, 
antacids, H₂ -receptor antagonists, PPIs and more seldom surgery (Figure 8) (112).  
 
Figure 8. Treatment of diagnosed GERD. H₂ blockers and Alginates can be used as 
needed in patients with minor discomfort. Disease that is more serious is treated with 
PPI for periods or continuously and in some cases with a double dose. Adapted from 
Tidsskr Nor Laegeforen (112).  
Proton pump inhibitor (PPI) 
PPI are the treatment of choice in patients with GERD affecting the quality of life. 




for meal-induced reflux and it increases over days. Short-term use has not been 
associated with complications. A restrictive attitude to long term treatment is 
recommended, and the dose should be kept as low as effective (112).  
The effect of PPI may be better in classical GERD than in EER 
PPI treatment at low doses once daily will elevate gastric pH to 6 or higher, but only 
for short periods. Higher doses twice a day seem to have a better effect.  
Histamine-2 receptor antagonists  
Hitamine-2 receptor antagonists give quick symptom relief through reduction of acid 
production in the stomach.  
Antacids 
Antacids neutralizes the acid in the stomach. The effect comes quickly but will not 
stop further acid production. 
Alginates 
Alginates make a mechanical barrier that protects against the postprandial acid 
pocket. Studies show significantly better effect compared to placebo. There does not 
appear an additive effect of supplying PPI treatment with alginates (113). 
Antireflux surgery 
Fundoplication was described first time in 1955. Anti-reflux surgery may reduce 
esophageal acid reflux significantly, but any long-term effect has been difficult to 
predict (114). Most patients achieve and remain in remission five years after 
laparoscopic antireflux surgery (115).  
Lifestyle intervention 
As behavioral factors may trigger GER episodes, lifestyle intervention may improve 
the disease (78). Moderate physical exercise and high intake of fiber seem to reduce 
the risk but systematic review on life style interventions concluded that only weight 
loss in obesity and head-of-the-bed elevation were effective. However, several 




obese, stop smoking, increase dietary fiber intake, avoid late evening meals, head-of-
the-bed elevation if supine reflux (87). Data on elimination of food that can trigger 
reflux is not available. 
4.5 The link between GER and the airways 
A possible association between GERD and the upper airways, was first described 
more than 100 years ago. In 1903 Coffin suggested that “post-nasal catarrh” may be 
caused by hyperacidity and gases from the stomach (116).  
It has been discussed for decades whether GERD, for some CRS-patients, can be a 
contributing factor. Holmes et al writes in the book, “The Nose”, from 1950 about a 
possible connection between GERD and the upper airways (117), and the precise role 
of GERD in CRS has been discussed since that time without reaching a consensus. 
Montréal definition of GERD defines the status up to 2006 (1).  
 Pathophysiological mechanisms linking GER and the airways 
Two different pathophysiological mechanisms have been suggested to explain how 
GERD may contribute to airway manifestation. A theory of direct cytotoxic effect of 
refluxate on the respiratory mucosa and a reflex theory suggesting a neural reflex 
from the esophagus to the upper airways via the autonomic nervous system (118, 
119).  
The theory of a direct toxic effect 
This theory implies there is a direct toxic effect from the refluxate on the airway 









Figure 9. One theory is that the refluxate has a direct toxic effect on the 
extraesophageal mucosa. In this illustration, pepsin from the stomach has reached 
the sino-nasal area. 
The mucosa outside the stomach has limited protective ability against gastric content. 
Thus, pepsin may induce inflammation in the respiratory tract with mucosal edema 
and impaired mucociliary function. In children, 24-hour pH monitoring has shown 
reflux to nasopharynx. Contencin and Narcy showed reflux above the 
cricopharyngeus which may support the existence of direct toxic effect of refluxate 
(120). The theory is further supported by detection of pepsin in saliva in pediatric 
patients with documented reflux and less pepsin in controls (110). Detection of 
pepsin in the middle ear of children with recurrent acute otitis media and/ or otitis 
media with effusions, is also in line with this theory (121).  
The reflex theory 
According to the reflex theory, there is a vago- vagal reflex from the esophagus to the 
airways via the autonomic nervous system. The existence of such a link is supported 
by studies made decades ago. Intra-esophageal acidic provocation did reduce airway 
flow and heart rate and increased pulmonary resistance in asthmatics (122, 123). 
Stimulation of the esophagus in guinea pigs with hydrochloric acid elicits 




nasal mucosal edema consequently gives ostial obstruction (125). Our results, with no 
important difference in pepsin, in nasal secretions and saliva, between CRS-patients 
and controls and no significant difference in pepsin in nasal secretion or saliva 
samples between CRS-patients with proximal reflux or not, may be in line with this. 
Reservations have to be made due to the possible limited sensitivity and specificity of 
the Pep-test (126). 
 The link between GER and inflammation of the lungs 
There is a high prevalence of GER in asthmatics, frequently without the classical 
symptoms of GERD. Pepsin has been detected in the lungs, and elevated level of 
pepsin from the lungs has correlated well to severe pulmonary symptoms (127)  
In a trial with PPI treatment of patients having both asthma and GER, there was a 
reduction of nocturnal asthma (62). In another study, a subgroup of asthmatics with 
concomitant diagnosed GERD may have significant improvement from PPI treatment 
(128). However, trials on treatment of asthma with PPI are diverging, and currently 
there is no evidence to support a routine use of PPI in asthmatics. 
 The link between GER and chronic cough 
Chronic cough may be initiated by aspiration of gastric content. Cough may also be 
due to distal esophageal stimulation, via a reflex mechanism (129). Although GERD 
is one of the most common causes of chronic cough, the diagnosing and treatment of 
GERD-related chronic cough can be challenging. Only a small proportion of these 
patients have the classical symptoms of GERD (130), but a high proportion have 
pepsin in saliva when tested immediately after an episode of cough (131).  
 The link between GER and laryngitis 
When the gastric content ends up more proximally in the laryngopharynx, it is called 
laryngopharyngeal reflux (LPR). LPR is relatively common and is frequently 
associated by laryngeal symptoms. In 2000, Koufman described that at least 50% of 
patients with laryngeal and voice disorders, referred to a tertiary voice center had 




and they had less than 40% heartburn and 25% esophagitis (81). More recently, 
Wang et al found pepsin in vocal cord polyps, concluding that pepsin may be a risk 
factor in their formation (132). Though the connection between GERD and laryngitis 
is well established, there is no consensus on treatment procedures.  
 The link between GER and otitis media 
A high incidence of pepsin in the middle ear cleft of children with otitis media with 
effusions (OME) led to speculations about a role of reflux in the pathophysiology of 
otitis media with effusion, and a role of anti-reflux therapy in patients with this 
diagnosis (133). Later, this was confirmed in a controlled trial of 509 of children with 
recurrent acute otitis media and/ or otitis media with effusions and a control group of 
64 pediatric patients. They found a high incidence of pepsin in the middle ear cleft of 
children with recurrent acute otitis media and/ or otitis media with effusions, 
compared to a control group (134). As GERD has been implicated in the 
pathophysiology of otitis media with effusion, authors have concluded that there may 
be a role of anti-reflux therapy in patients with otitis media with effusion (121). 
Helicobacter Pylori (H. Pylori) has been detected in the middle ear in OME and may 
be a marker of reflux. Thus, the bacteria have a possible role in the pathogenesis of 
OME (135). 
 The link between GER and obstructive sleep apnea syndrome 
(OSAS) 
OSAS is characterized by episodes of pharyngeal collapse during sleep, with ceasing 
airflow. These patients have a high incidence of nightly reflux. When treating with 
continuous positive airway pressure (CPAP) the reflux is reduced. The mechanisms 
of GER in OSAS are not fully understood, but obesity is predisposing for both 
diseases. Negative intrathoracic pressure and repetitive arousals may also play a role 
(136). As only a proportion of nocturnal GER episodes are associated with apneic 
events, and studies on the relationship between GER and OSAS are diverging, a 




 The link between GER and dental erosions  
Dental erosions is considered an established complication to GERD (1). Reported 
prevalence in patients with symptomatic GERD is between 17% and 68% (138) and a 
prevalence of 29% (139) is seen in European adults without the classical symptoms 
of GERD. As measured with impedance pH monitoring and endoscopy, the majority 
of patients with dental erosion had GERD (138).  
 The link between GER and CRS 
Looking for a link between GER and CRS, it has been suggested that three criteria 
should be met.  
1. Patients with CRS should have a higher prevalence of GER than healthy 
controls. 
2. Biologically plausible pathophysiological mechanism should explain the link 
(Figure 10). 
3. If GER is a contributing factor to CRS, clinical manifestation of suspected 
GERD-related CRS should respond to anti-reflux therapy (119).  
Our study on nose- and sinus-related quality of life in GERD, showed that the former 
was reduced in CRS-patients compared to heathy controls, as measured with SNOT-
20. The study supported a coexistence of GERD and CRS (140). Contencin and 
Narcy were the first to demonstrate acid reflux in children with chronic 
rhinopharyngitis (120). Patients with a refractory CRS have more symptoms of 
GERD (141), and in CRS-patients undergoing FESS, GERD was a predictor of poor 
outcome of the surgery (142). In pediatric patients, Phipps et al found that 63 % of 
those suffering from CRS had GER (143). A questionnaire-based trial found 
nocturnal GERD to be a risk factor of developing rhinitis and rhinosinusitis (144).  
Adult patients with refractory CRS have more reflux compared to a control group as 
measured with pH-monitoring (145). Frequent episodes of proximal reflux found by 
24-hour multichannel intraluminal pH-monitoring in CRS-patients compared to 




nasal pepsin in CRS-patients has been regarded as a proof for an association between 
GERD and CRS (79). These findings support that a direct toxic effect of refluxate 
may be a pathophysiological mechanism in CRS. Our controlled trial using Peptest 
for this purpose did not reproduce these results, concluding that this may be due to 
low specificity of the test (126).  
As lifestyle intervention may increase the tension in LES and reduce the occurrence 
of TLESR, they may also improve GERD-related CRS. We have not seen that this 
aspect investigated. The effect of anti-reflux therapy in CRS is better documented in 
children than adults. Bothwell et al. found that, in children with CRS who were 
candidates for surgery, 89 % experienced symptom relief after anti-reflux therapy and 
were able to avoid an operation. They concluded that GERD should be considered 
and treated medically before surgery in children (147). Phipps et al. found that 15 of 
19 children diagnosed with both GERD and CRS improved regarding CRS- 
symptoms after medical reflux therapy (143).  
DiBaise found retrospectively, an improvement of sinus symptoms in two thirds of 
adult patients with clinically refractory CRS with GERD after PPI or anti-reflux 
surgery. Only the patients who had abnormal esophageal pH-monitoring had 
improvement of their sinus symptoms (148). These results were not reproduced in a 
later controlled pilot trial (149).  
Repeated treatment studies have recommended higher doses and longer period of 
treatment when treating EER, CRS included, before evaluation of effect (81, 150, 
151). PPI b.i.d. when treating EER is recommended considered in some patients after 





Figure 10. This illustration of GER in CRS indicates that the refluxate provides an 
inflammation of the sino-nasal mucosa. The inflammation may be induced by a direct 




5. Aims of this thesis 
5.1 General aims: 
The main aim of this research was to obtain a better understanding of the role of GER 
in CRS and to get a final answer to the question: Is there an association between 
GERD and CRS? 
5.2 Specific aim Paper I 
We wanted to investigate the sino- and nasal-quality of life in patients with 
gastroesophageal reflux disease (GERD) compared to a control population. 
5.3 Specific aim Paper II 
We wanted to monitor the occurrence of reflux in CRS-patients by using with the 
most reliable method for this purpose. We considered 24-hour esophageal 
multichannel impedance pH-monitoring to be the best choice. 
5.4 Specific aim Paper III 
We wanted to evaluate the presence and level of pepsin in sputum and nasal secretion 
in CRS-patients compared to age and gender matched healthy controls and consider if 




6. Subjects and methods 
6.1 Study design and subjects 
This thesis is based on three prospective controlled studies. In the first, consecutive 
adult patients referred to Gastro Nova, a specialist clinic in gastroenterology, were 
included if fulfilling the criteria of having GERD with esophagitis. We investigated 
the nose- and sinus-related quality of life in these patients by using SNOT-20. The 
patients filled out the form in the gastro outpatient clinic immediately after 
gastroscopy. 
In study number two and three, consecutive adult patients with CRS referred to the 
ENT department at Stavanger University Hospital, were included after informed 
consent. In study number two, the CRS-patients went through a 24-hour impedance 
pH-monitoring. The results were compared with healthy controls from an existing 
European database collected by French and Belgian clinicians (103). In the third 
study, we analyzed and compared pepsin in nasal secretions and saliva in CRS-
patients and age and gender matched healthy controls. 
Ethics and approval 
The study was conducted according to the guidelines given in the Helsinki 
declaration. The Regional Norwegian Committee for Medical and Health Research 
Ethics (REK Vest 2010/2030) approved all procedures.  All participants were 
included after written informed consent. 
Nose and sinus-related quality of life in GERD (Paper I) 
Patients with suspected GERD, referred to Gastro Nova, a specialist clinic in 
gastroenterology, were included in the study after positive gastroscopy. The patients 
fulfilled the criteria for GERD (1) and had a positive gastroscopy. The esophagitis 
was staged according to the Los Angeles (LA) classification; Grade A: mucosal 




B: mucosal breaks > 5 mm long and do not extend between the tops of two mucosal 
folds, grade C: mucosal breaks that is continuous between the tops of two or more 
mucosal folds but which involves less than 75% of the circumference, grade D 
mucosal break which involves at least 75% of the esophageal circumference (97). 
This is the most widely used system to endoscopically grade GERD (152).  
Seventy-seven patients were included, 44 men and 33 women, median age 50 years, 
ranging from 19 to 83. Fifty-two were classified as LA grade A, ten as grade B and 
15 as grade C. 
480 randomly selected teachers were included as healthy controls, 183 men and 297 
women, median age 43 years, ranging from 20 to 75 (Table 2). 




Healthy control subjects, 
N=480 
Age, median (IQR), years 50 (39-61) 43 (35-54) 
Sex, Women/ Men 33/45 297/183 
IQR= Interquartile Range  
The enrolment of patients took place in the period 2008- 2009. The enrolment of 
healthy controls took place in the same period. 
Impedance pH-monitoring (Paper II) 
Consecutive patients with CRS according to the criteria given by EPOS 2012, above 
18 years of age who were referred to the ENT department, Stavanger University 
Hospital were invited to participate. GERD with ongoing treatment for reflux was an 
exclusion criterion. Symptoms of reflux or prior sinus surgery were not. Twenty-one 
women and 25 men were included, median age 47 years, ranging from 23 to 73 




The control subjects were participants in a European study published in 2013, 22 men 
and 23 women, median age 47 ranging from 18 to 78 (Table 3). 




Healthy control subjects, 
N=45 
Age, median (IQR), years 47 (40-58) 47 (35-58) 
Sex, Women/ Men 21/25 22/23 
BMI, median (IQR) 25.1 (23.5-26.1) 24.0 (21.9-25.0) 
IQR= Interquartile Range BMI= Body Mass Index 
All patients were informed and examined by the same investigator. The patients 
completed 24-h impedance pH-monitoring, with reliable recordings for 18-25 hours. 
Pepsin measuring (Paper III) 
Consecutive patients with CRS above 18 years, referred to the ENT department, 
Stavanger University Hospital were invited to participate. Sixty-two patients were 
included, 33 men and 29 women. Age and gender matched healthy controls were 
recruited among patient’s friends, neighbors, colleagues, at different jobs and among 
the investigator`s friends, family, colleagues and parents of children’s associates. The 
enrolment of patients and healthy controls took place in the period 2013- 2017. 
Median age in patients and healthy controls was 46 (ranging 22-73) and 46.5 (ranging 







Table 4. Demographic data of the patients and healthy controls in the pepsin study 
 CRS-patients, 
N=62 
Healthy control subjects, 
N=62 
Age, median (IQR), years 46 (36-56) 46.5 (36-54) 
Sex, Women/ Men 29/ 33 29/ 33 
BMI, median (IQR) 25.1 (23.5-26.9) 25.9 (23.3-28.4) 
IQR= Interquartile Range BMI= Body Mass Index 
Exclusion criteria was GERD with anti-reflux medication on a daily basis.  
Symptoms of reflux were not an exclusion criteria per se. Nasal corticosteroids were 
not allowed the day of investigation.  
6.2 Methods 
 Questionnaires 
All the questionnaires used are presented in the appendix 
20-item Sino-Nasal Outcome Test (SNOT-20) 
SNOT-20 was used in all the trials in this thesis. It is a validated, self-administered 
quality of life instrument specific for symptoms of rhinosinusitis and sensitive to 
clinical changes. It describes the health burden of rhinosinusitis by measuring; 
physical problems, functional limitations and emotional consequences of CRS by 
asking the participants to score 20 key symptoms. These are: the need to blow the 
nose, sneezing, runny nose, cough, postnasal discharge, thick nasal discharge, ear 
fullness, dizziness, ear pain, facial pain/ pressure, difficult falling asleep, waking up 
at night and difficulty falling asleep. With reference to symptoms the two last weeks, 
the participants scored each symptom from 0-5, giving a summery score, the total 
SNOT-20 score (52). A 22 items questionnaire, SNOT-22 (53) is available in 




Visual Analogue Scales (VAS-CRS)  
VAS-CRS is a psychometric response scale used to measure subjective characteristics 
of sino-nasal symptoms. It includes the rating of twelve symptoms related to nose and 
sinuses as well as obstructive sleep disorders on a 100 mm VAS with endpoints 
“never” (0) and “always” (100). Each subject was asked to grade each symptom and 
condition by frequency. VAS 0-3 is defined as mild disease, >3-7 as moderate disease 
and VAS >7 as severe rhinosinusitis affecting the patient´s quality of life defined in 
EPOS 2012 (2).  
Gastro-esophageal Reflux Disease Questionnaire (GerdQ) 
GerdQ was used to record classical symptoms of GERD. It is a six-item validated, 
self-assessed questionnaire regarding frequency of symptoms typical for reflux the 
last seven days (90, 91). It is developed from the 22-item questionnaire Reflux 
Disease Questionnaire (RDQ), a self-assessed questionnaire developed to diagnose 
and evaluate GERD in general practice (89). It is valid as a diagnostic tool for GERD 
with reduced health care costs compared to endoscopic approach. In a trial from 
2012, the authors found that by using the GerdQ, they reduced health care costs (90). 
GerdQ may not capture atypical symptoms of GERD. Scores above eight indicate 
reflux disease.  
 Twenty-four-houre esophageal impedance pH-monitoring 
Twenty-four-hour combined esophageal pH- and impedance-monitoring is regarded 
the gold standard for investigation of GERD (101). As reflux is best detected by 
impedance and its acidity best characterized by pH-monitoring, we chose this method 
in our trial. 
Intraluminal impedance monitoring allows detection of gastro esophageal-reflux 
based on changes in resistance to electrical current flow between two electrodes, as 
liquid and/ or gas bolus moves between them. A 50 % drop in impedance from 
baseline, seen as a retrograde move along the catheter starting distally characterizes 
an episode of reflux. As the refluxate flows back into the stomach, a rise in 




during an episode of reflux leaves a typical measuring pattern (Chapter 4.4.4, Figure 
7a-7d).  
The number of distal reflux episodes and the number of reflux episodes with 
proximal extent, defined as reaching the impedance electrodes 15 cm proximal to the 
LES, were recorded. Bolus exposure was calculated as percent of total recorded time. 
We differentiated between reflux when recumbent or upright, as well as acidic 
(pH<4) or non-acidic (pH>4) reflux. 
The impedance pH-catheter was positioned trans-nasally into the esophagus with the 
proximal pH-electrode located five cm above the LES and one in the stomach. The 
impedance electrodes were positioned 2, 4, 6, 8, 10, 14, 16 and 18 cm above the LES. 
As impedance was monitored between two electrodes, it was monitored at six 
different levels (Figure 11). The participants had an overnight feast before 
undergoing esophageal manometry to localize the level of the upper and lower 
esophageal sphincters (UES/LES). 
 
Figure 11. 24-h impedance-pH 
monitoring, showing the catheter 
in the esophagus with eight 
impedance electrodes giving six 
measuring points and an external 




Patients completed the 24-h combined pH-impedance monitoring, with recordings for 
18 - 26 hours. The impedance pH-catheter ZAN-BG-44 (Sandhill Scientific, Inc; 
Highland Ranch, CO, USA) was used. 
The participants were encouraged to maintain normal daily activities and take meals 
as usual during the recording. They were asked not to drink beverages with a pH<4 
between meals. A data logger (Sleuth, Sandhill Scientific Inc.) (Figure 11) was used 
to record meal times, changes in posture and the occurrence of the following specific 
symptoms: regurgitation, chest pain, cough and the need to clear the throat. We 
scored the symptom-reflux time in line with the Symptom Index (SI) (153) and 
Symptom Association Probability (SAP) (154). 
The healthy controls underwent a similar study protocol for 24-h esophageal 
impedance pH-monitoring (103).  
The analysis was performed with BioView version 5.4.3 (Sandhill Scientific Inc.). 
They were done automatically with the Autoscan function of BioView, and then hand 
edited by two investigators. Each control person was also analyzed manually by the 
same two investigators.  
Measuring pharyngeal reflux has been attempted, but the investigational techniques 
are difficult and poorly reproducible (103). Thus, such recordings were not included 
in the present study.  
 Peptest 
As twenty-four-hour impedance pH-monitoring is a resource consuming procedure 
and promising results on pepsin monitoring as an alternative diagnostic procedure of 
GERD appeared, we wanted to examine this in EER.  
We used an enzyme immunoassay, Peptest® (RD Biomed Ltd, Cottingham, UK), 
recommended for detection of pepsin in saliva. This non-invasive test is based on a 
lateral flow device technology. It contains two different monoclonal antibodies to 




(71, 131). A control band on the device indicates a correctly performed test and a 
second line indicates presence of pepsin in the sample, defining a positive or negative 
test. The intensity of this line is proportional to the quantity of pepsin, and by using a 
reader, LFDR101, the concentration of pepsin in ng/mL is obtained (131). Both the 
sensitivity and specificity of Peptest has been estimated to be 87 % (106) but recent 
literature suggests the sensitivity to be 78,6 % and the specificity to be 65% (155). 
The lower limit for detection of pepsin with Peptest is 16ng/ mL given by the 
manufacturer (131). To the best of our knowledge, Peptest has not previously been 
used on nasal secretions.  
CRS-patients and healthy controls delivered three tubes with saliva and three tubes 
with nasal secretions (roughly 1 mL in each) for pepsin analysis. We strictly followed 
the recommendations from the manufacturers; “Sample one should be taken in an 
upright position within 15 minutes of waking up from overnight sleep before eating 
or brushing teeth. The second sample should be taken one hour after the main meal of 
the day and the third sample should be taken one hour following the next main meal 
of the day” (155). This gave a total of three saliva samples and three samples of nasal 
secretions per subject. Subjects without rhinorrhea or not having enough nasal 
secretions to create samples from the nose, used 0.5 ml sterile water for irrigation of 
each nostril. They were asked to inform whether they used sterile water in the nose or 
not. Unfortunately, this information is missing in a large proportion of both patients 
and healthy controls. However, roughly 45 % of the patients did use water for 
irrigation, slightly more of the controls (Table 5).  
 
Table 5. Percent of patients and controls that used sterile water, 0.5 ml in each nostril 
before collecting the nasal sample. 
 Pas A1 % Pas A2% Pas A3% Con A1% Con A2% Con A3% 
no 13,5 12,2 14,9 10,8 16,2 17,6 
yes 45,9 45,9 35,1 56,8 50,0 48,6 




The tubes for investigation contained 0.5 mL of 0.01 M citric acid for conservation, 
and the participants stored the samples in a refrigerator until analysis. As 
recommended the samples were analyzed within seven days after they had been 
collected (106).  
Each sample was centrifuged at 5000 rpm for five minutes (Figure 12 a), 80 µl of the 
supernatant was extracted, and 240 µL buffers were added. This was vortex-mixed 
(Figure 12 b) for ten seconds before 80 µL was transferred to the pit of the Peptest 
device (Figure 12 c). The test was read as positive or negative after 15 minutes and 
quantification done by the LFDR reader (Figure 12 d). 
  








Figure 12 d. The LFDR-reader 
used for quantification of 
pepsin detected with the 
Peptest device. 
Figure 12 c. Eighty µL solution 
transferred to the Peptest device. 
 
Figure 12 b. Vortex mixer. Figure 12 a. The centrifuge used 





In samples with no supernatant layer, 500 µL buffer was added, and the sample was 
Fortex mixed for ten second and centrifuged a second time at 5000 rpm for five 
minutes. If a supernatant layer appeared, the procedure as described was performed, 
if not, another 500 µL was added and centrifuging repeated as recommended by the 
manufacturer (personal message from Dettmar and Woodcokk, RD Biomed Limited). 





6.3  Statistics 
Descriptive data are reported as median with inter-quartile range, mean with standard 
deviations and counts with percentages, as appropriate. As data in these studies 
generally were not normally distributed, non-parametric methods were used. The 
analyses were done using SPSS (Statistical Package for Social Sciences, Chicago, 
USA), SPSS ver. 23 (Paper I and II) and SPSS ver. 24 (Paper III). 
Prior to the studies, we performed sample size calculations, in order to decide the 
minimum sample size needed to recognize a given difference between groups.  In 
trial one and two, we had an already collected number of healthy control subjects 
included in this calculation. 
In the analyses of subgroups, there are lower number of participants, hence the 
statistical power of these analyses is lower. 
In trial 1 and 2, the data were not normally distributed, and we used Mann-Whitney U 
test for differences between patients and controls. 
The data in trial 3 were also not normally distributed. As the data were collected as 
age and gender matched, we used the paired samples Wilcoxon for continuous data 
and McNemars test for categorical data. To calculate correlation between variables, 
we used Spearman’s Rank Order Correlation. In all hypothesis tests, a p value less 





7. Summary of results 
7.1 Results Paper I 
Patients with GERD had significantly higher total SNOT-20 scores compared to a 
control group. Median total SNOT-20 score in patients was 22.1 and in healthy 
controls 5.0 (p<0.005). Hence, they had a reduced nose- and sinus-related quality of 
life compared to the control group. We also found significant higher SNOT-20 scores 
in the patient group when omitting the possible sleep-related questions in the 
questionnaire. Accordingly, this study indicated that there may be an association 
between GERD and CRS. 
7.2 Results Paper II 
CRS-patients had significantly higher incidence of abnormal gastroesophageal reflux 
compared with asymptomatic controls. The esophageal acid exposure in percent of 
time in patients compared to healthy controls was 7.3 and 1.4 respectively (p<0.03). 
The number of events with proximal reflux was higher in patients compared to 
controls, median 34 and 3 respectively (p<0.0005). The results of this study 
suggested that GER might be a causative or contributing factor of CRS. 
We found evidence of more GER in all patients compared to controls as measured 
with both acid exposure in percent of time, number of reflux episodes, bolus exposure 
in percent of time and especially large difference between the groups in proximal 
extent of the refluxate. 
7.3 Results Paper III 
As measured by Peptest, we found frequently positive Peptest and high levels of 
pepsin in saliva and nasal secretions in CRS-patients and healthy controls. However, 




healthy controls, nor in those with high GerdQ scores or verified proximal reflux. 
There was no correlation between pepsin and GER as monitored with 24-h 
impedance pH-monitoring. We found a high degree of variation of the 
concentrations, both in CRS-patients and controls. 






8.1 Study design 
The three papers in this thesis are based on three different studies where a prospective 
control design was used, all having different approaches to the issues of the thesis. 
The design can give important contribution in evaluating a hypothesis, but when 
interpreting the data, caution must be taken, particularly in establishing a relationship 
between cause and effect.                                                                                                                                       
8.2 Selection of patients and control subjects 
We have strongly focused on the selection of participants to ensure external validity. 
All patients and controls were included after information and written consent. 
 Patients 
The patients in study number one were included after fulfilling the criteria of having 
GERD according to classical symptoms and pathological gastroscopy findings. We 
recruited patients from Gastro Nova, a specialist clinic in gastroenterology in 
Stavanger, Norway. As all invited patients accepted to participate, there should not be 
a selection bias. Only patients with a positive diagnosis of reflux esophagitis by 
gastroscopy were included. 
All patients in study number two and three were included from the ENT department, 
Stavanger University Hospital. They had CRS according to EPOS 2012 (2). We did 
not distinguish between CRSwNP and CRSsNP, and prior sinus surgery was not an 
exclusion criterion. Only ten of the CRS-patients declined. The reasons were long 
distance to hospital and unwillingness to swallow the probe.  
 Healthy control subjects 




In study number one, the controls were all schoolteachers at different schools in Vest 
Agder County, Norway, included after information and written consent. A co-author 
visited the schools, gave instructions about how to complete the questionnaires and 
collected them afterwards. By this, nearly all present teachers participated, and no 
forms were lost.  
Teachers have an average level of education, an average level of income, and a 
reasonably equal distribution of males/females in the Norwegian society. They were 
therefore considered applicable as controls in this these studies.  
The control population in study number two was an already existing material used by 
European clinicians as the normal values for 24-hour impedance pH-monitoring.  
The control population in the third case-control study was enrolled in the Stavanger 
area in the same period as the patients were recruited. To ensure external validity, 
they were included from different arenas. They were teachers, store employees, from 
various offices and among the PhD candidate and patient’s friends and colleagues. 
The healthy controls were age and gender matched to the patients in the study. 
8.3 SNOT-20 
We used the 20-item questionnaire “sino-nasal outcome test-20” (SNOT-20) (52) and 
not the more recent SNOT-22 (53), as the former was validated in Norwegian, and 
the latter was not at the time of investigation. The differences between the two 
questionnaires are questions about nasal blockage and the loss of sense of taste and 
smell in the latter. It is hard to imagine that the lack of these questions may have 
made any significant effect on the outcome of the present investigations. However, as 
there is a significant association between disturbed sleep and GERD (156), sleep 
quality could be a potential bias (157). To exclude this possible source of error, we 
also compared the groups omitting the sleep-related questions. The difference 
between patients with GERD and the healthy controls was still significant with 




As there was a preponderance of women in the control group (61.9%) and men 
(57.7%) among the patients, we checked if differences in sex could explain the 
differences between the two groups. We did not find any statistically significant 
differences in SNOT-20 score between men and women, not amongst patients, nor 
amongst controls.  
As the age was lower in the control group compared to the patient group, median age 
43 and 50 respectively, it may be speculated whether this may affect the SNOT-20 
outcome. The differences in age were small, but due to the large sample sizes, they 
were significant (p=0.04). When separating the patients and controls in two groups, 
above and below 50 years, we did however not find any significant differences in 
total SNOT-20 score between the groups.  
We also separated the patients and controls in other age groups (above and below 40 
years and above and below 60 years) without finding significant difference in total 
SNOT-20 between the ages. Accordingly, there is no indication of any age effect in 
the SNOT-20 score in this study.  
Seventy-seven out of 100 patients participating in the study had endoscopic findings 
indicating reflux esophagitis. The other 23 patients had not and were not included in 
the analysis. There was no difference in SNOT-20 score between these groups. This 
may be explained by the fact that the gastroscopy will only capture the patients with 
GERD and visible lesions (158). We included patients after positive gastroscopy, and 
we may have excluded patients with reflux, but without evidence of mucosal damage.  
Our results are supported by another study using SNOT-20 to compare symptoms of 
post-nasal drip (PND) with 24-hour esophageal, nasal and laryngeal pH-monitoring. 
They found PND to be associated with reflux (159).  
Generally, history, pH-monitoring and / or gastroscopy may establish the diagnosis of 
GERD. In the SNOT-20-study, the patients were included based on symptoms of 




high specificity of 97% (152, 158). Accordingly, it is reasonable to believe that the 
patient included really had GERD and thus, that we have given a description of the 
sino-nasal quality of life in a relevant group of patients and compared them with a 
relevant group of healthy controls.  
8.4 Twenty-four-hour esophageal impedance pH-
monitoring 
It has been debated to what extent automatic analysis of impedance data with 
software such as Autoscan® (Sandhill Scientific Inc.) is reliable and comparable to 
manual analyses. A software program must be able to distinguish between impedance 
changes due to real reflux and changes due to non-reflux phenomena such as 
swallowing, artifacts and random changes in intra-esophageal impedance. The 
software seems to have improved over the years in this respect as there is only minor 
variability between hand-editing with Autoscan versus Autoscan alone. Still, today, 
the former is recommended (160). Zerbib et al. found also a small inter- observer 
discrepancy of proximal events between different investigators. This was due to both 
missed events and misdiagnosed events, based on different interpretations of 
impedance drops within the esophagus (103). Never the less, the overall 
correspondence between manual and automatic analyses was good (161).  
To reduce the possible bias because of different investigators analyzing the two 
groups, patients and controls, we combined automatic and manual analysis of 
patients´ recordings and agreed about the evaluation of each (Figure 13). We 
removed a percentage of proximal episodes that we could not accept as indicative of 
reflux but did not inspect the entire recording for possible missed events. This might 





Figure 13. Example of an episode of proximal reflux as identified with impedance, a 
fall in impedance starting at the distal measuring point and the increase of 
impedance starting proximal as the refluxate is returning to the stomach. 
Furthermore, one of the two scientists that did the analysis had previously done 
similar analyses with the French group that handled the control data. This is likely to 
have increased the reliability of the interpretation. 
There has been an assumption that the prevalence of GERD in North America is 
higher than in Europe, and furthermore that physiological reflux may be more 
pronounced. These geographical variations have been explained by cultural and 
dietary differences (Shay, Tutuian et al. 2004), and were the background for 
establishing a European database for normal pH-impedance values. However, the 
total number of reflux events detected by impedance in the European and the North 
American studies, were very similar and gave no support to the theory of differences 
between the populations (103, 104). The European control material used in this trial 
is used all over Europe for similar investigations. Hence, lacking our own normal 
data, this was the best way for us to perform a controlled study. Professor Frank 
Zerbib at the University of Bordeaux generously offered us full access to the entire 




We have focused on impedancemetry, more than pH-monitoring in this study, since 
we took particular interest in proximal extent of reflux. As we found high incidence 
of non-acid or weakly acidic exposure as measured with pH-impedance, and 
especially abnormally high number of proximal reflux episodes, it was interesting to 
know if that observation was in line with traditional pH-measurements. All the 
patients with pathological acid exposure, defined as having acid exposure time (AET) 
(time below pH 4.0), AET > 7,3 % of recording time, did also have abnormal 
proximal reflux defined as number of episodes > 15.5/ 24 hours (Figure 14 a). Upper 
limit of normal based on the control group from Bordeaux is higher than the Lyon 
Consensus values (> 6% abnormal, 4- 6% borderline). The results of acid exposure 
combined with distal reflux estimated as number of distal impedance events is shown 
in Figure 14 b. Bolus exposure in percent of time combined with acid exposure is 
shown in Figure 14 c. 
 
Figure 14 a. Characteristics of the patients with proximal reflux as measured 
with 24-hour impedance pH-monitoring. All patients with pathological acid 
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Figure 14 b. Results of 24-hour impedance pH-monitoring for the distal 
esophagus. Distal impedance results are based on number of episodes, and 
acid exposure are based on percent of time.   
 
 
Figure 14 c. Bolus exposure and acid exposure, percent of time as measured 
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If defining pathological acid exposure as AET > 6%, according to the Lyon 
Consensus (162) there is a higher number of patients included, and more if 
considering all patients with AET > 4%. Seven patients had AET >7.3% and ten had 
AET > 6% (additional three patients had AET between 4% and 6%). All except one 
patient with AET> 4%, had number of proximal reflux episodes of at least 22. As the 
95th percentile in the European normal data from 2005 is higher than in our control 
material, it is interesting to know how many of our patients had an abnormal 
proximal reflux with these data as the reference. We had 22 patients with a number of 
proximal reflux episodes of 30 or higher. This is lower than the 34 patients we first 
measured as having abnormal proximal extent of the refluxate, but still a very high 
percentage of patients. When defining abnormal AET as > 6% of time and abnormal 
proximal reflux as > 30 episodes, the difference between the two is less. Abnormal 
distal acid exposure has traditionally been regarded as higher evidence of GER 
compared to number of reflux episodes as measured with multichannel impedance 
monitoring, and the proximal extent of impedance events as the least. Abnormal time 
association of symptom and reflux time (Symptom Association Probability=SAP) has 
been thought to provide the ultimate proof of GERD (Figure 15 and 16). The 
evaluation of SAP as parameter is more appropriate in investigation of classical 
reflux symptoms compared to investigation of EER, as it may be more difficult to 





Figure 15. Evidence of GER is highest at the bottom of this figure. Increasing evidence 
of GER: Abnormal number of proximal reflux events, abnormal number of distal reflux 
events, abnormal distal acid exposure and SAP. SAP at the bottom of this figure has 
highest evidence of GER and abnormal proximal reflux, at the top, has the lowest. 
 
Figure 16. The percent of patients with abnormal number of proximal extents of 
refluxate, abnormal number of reflux episodes, abnormal bolus exposure and 
abnormal distal acid exposure as measured by pH impedance monitoring in our trial. 






In the diagnosis of EER, the proximal extent, with lowest evidence may be the most 
interesting parameter to investigate. This is due to speculations of the origin of the 
airway symptoms in EER. As the upper esophagus has nerve endings more 
superficial compared to the distal part (163, 164), a proximal extent of refluxate may 
have influence on more nerve endings and may more easily induce a reflex 
inflammation to the airways. The occurrence of proximal extent of refluxate might 
also support the theory that the refluxate has a direct toxic effect on the 
extraesophageal mucosa. 
8.5 Peptest in evaluation of pepsin in saliva and nasal 
secretion  
The same investigator handled all samples from all subjects and performed all the 
analysis with Peptest to ensure quality at all levels of the investigation. The 
investigator knew whether a test belonged to a patient or a healthy control. This lack 
of blinding may in principle be considered as a weakness of the study. On the other 
hand, it is difficult to imagine how this may have affected the outcome of the 
investigation.  
The high number of positive Peptests, both in patients and controls, supports a high 
incidence of physiological, postprandial reflux. As we know that everybody has small 
amounts of GER, especially after meals, and most often without having symptoms 
from the esophagus (1), it is relevant to question if this still may give symptoms from 
the airways. Positive Peptests, both in those with and without CRS, may indicate 
differences in sensitivity to refluxate, so that a certain level of pepsin might create 
disease in some people, but not in others (68). This includes the upper airways. If 
there are differences in vulnerability to pepsin, pepsin might contribute to the 
development of CRS in certain predisposed individuals, but not in others. 
The technical sensitivity of Peptest is confirmed to be high (106). However, the 




pepsin measurement in saliva is most reliable when collected at time of symptoms 
(165). Hence, Peptest gives snapshot information about the presence or absence of 
pepsin in saliva. In EER, the recommendation of obtaining the saliva samples soon 
after a reflux event (110) is difficult to accomplish practically. As reflux appears 
mostly postprandial, and corresponding symptoms of GERD are most common one to 
two hours after meals (166), we followed the recommendations from the 
manufacturer and tested post-prandial and immediately after waking up in the 
morning (to cover the nocturnal period) (155). Hence, any episodes of reflux at other 
times of the day may not have been detected.  
Peptest specificity appears to be lower than previously estimated (106, 108). It can be 
speculated whether the characteristics of the test may have changed over time. The 
main reason for these speculations is the surprisingly high incidence of positive 
Peptest and high concentration of pepsin in samples from both healthy controls and 
CRS-patients. Differences in handling procedures of samples from patients and 
controls cannot explain these results. The number of days between collected sample 
and performed analysis was almost similar between the two groups, the median in 
CRS-patients was 3.0 days and in controls 3.5, both well within the recommendations 
of the manufacturer.  
If a supernatant layer appeared, the procedure as described was performed. If not, 500 
µL migration buffer was added and centrifugation repeated, as recommended by the 
manufacturer. As adding extra buffer gave a significant extra volume, and therefore 
theoretically could have given a lower concentration of pepsin, this was 
systematically evaluated and corrected for, again as recommended by the 
manufacturer, by multiplication of the concentration with 1.5, and 2.0 if buffer was 
added twice.  
The present study raises important questions about the validity of Peptest as a 
screening method for extra-esophageal reflux. We strictly followed the 
recommendations from the manufacturers and found high levels of pepsin in both 




in controls compared to patients. If Peptest were a reliable method for pepsin 
detection in order to diagnose EER, we would also have expected to find more tests 
that were positive in patients with abnormal proximal reflux as evaluated by 24-h 
impedance pH-monitoring compared to those without. We did not. Furthermore, we 
would also have expected to find fewer positive tests and lower concentrations of 
pepsin in healthy controls. 
The significantly higher concentration of pepsin in the saliva of healthy controls 
compared to patients could be explained by the fact that reflux may induce 
hypersalivation (72). The hypersalivation may dilute the saliva (73), and the 
concentration of pepsin particularly in patients and thus, act as a confounder in the 
study. 
As there was no correlation between Peptest results and GerdQ scores, or Peptest and 
24-hour impedance pH-monitoring results, Peptest could not distinguish between 
physiological reflux and truly normal GER in our study. 
Another research group has recently performed nasal and salivary pepsin measuring 
with Peptest on patients suffering from non-allergic rhinitis. All patients had positive 
Peptests, most frequently in the postprandial samples (70.79 %). They found a clear 
association between non-allergic rhinitis and GERD based on high pepsin 
concentrations and concluded that Peptest had a higher specificity compared to RDQ 
(167). In contrast to our study, this study was not controlled. 
Recently, Sifrim`s group published a trial aiming to confirm previous data on high 
specificity of Peptest in healthy control subjects and patients with heartburn. They 
concluded that the test is not ready for clinical application due to frequently positive 
Peptest in healthy controls. Seventy-two percent had at least one sample with pepsin 
concentrations > 210 ng/mL (168). These results are in line with our study. Fifty-two 
% of our healthy controls had at least one salivary sample with pepsin concentration 




8.6 General discussions 
One of the main challenges when evaluating the role of GER in the pathogenesis of 
CRS are the sensitivity and specificity of the diagnostic procedures of the former. To 
comply with this, we have tried to combine different diagnostic strategies. 
By doing so, we have obtained new insight in the field. However, evidence for a 
causality between GER and CRS is still lacking. CRS is a disease of multifactorial 
origin. Hence, a confirmation of a single etiological factor, which may apply to a 
limited number of these patients, may be difficult. We believe that future progress in 
this field depends on improved diagnostic procedures for EER, and further 






The high SNOT- scores in the patients with GERD compared to healthy controls 
indicate a high incidence of CRS in GERD and a possible link between the two. This 
is supported by the findings of higher incidence of abnormal gastro esophageal reflux 
in CRS-patients compared to asymptomatic controls, in particular the abnormal 
proximal extent of the refluxate in the patients. The pathological mechanism may be 
either a vasomotor reflex from the proximal esophagus to the upper airway or a direct 
toxic effect of the refluxate on the airway mucosa. Peptest could not confirm the 
latter alternative, although it could not exclude its existence.  
High concentrations of pepsin in nasal secretion and saliva in both CRS-patients and 
controls, and the lack of correlation between proximal reflux and positive Peptest 
indicated a limited validity of the test for this purpose. 
As CRS is a disease of a multifactorial etiology, the evaluation of GER in CRS is 




10. Future perspectives 
There is still a debate to what extent and how GER could be a contributing factor for 
CRS. We need more research in this area, and there are several unmet research 
questions for scientists to address. 
The twenty-four-hour impedance pH-monitoring showed significantly more reflux in 
patients having CRS, compared to healthy controls. We hoped to see that the Peptest, 
as a quick and easy-handled diagnostic procedure would confirm this. Then, oto-
rhino-laryngologists would have had a simple tool for selecting the patients with 
refractory CRS and GER to optimize the treatment. Unfortunately, Peptest does not 
appear to have the qualities necessary to be that tool. Hence, the search for 
alternatives should continue. 
The novel diagnostic procedure, esophageal mucosal impedance (MI), measuring 
epithelial damage caused by reflux, may contribute with valuable information in 
future research. The MI, in combination with improved quantitative pepsin measuring 
and twenty-four-hour impedance pH-monitoring, may also provide more insight in 
the role of GERD in CRS. 
Reflux may depend on lifestyle. As e.g. obesity and some foods may increase it, the 
way we are living our lives has an impact on GER. Lifestyle intervention may 
increase the pressure of LES and reduce the frequency of TLESRs. Weight loss is 
well documented to improve GERD, but data on the efficacy of elimination of certain 
predisposing foods is lacking. Further, to what extent lifestyle interventions 
recommended in the treatment of GERD may favorably affect GERD-related CRS is 
unknown. This should be explored. 
There are cases of refractory CRS where reflux may be involved, and where medical 
measures against the sino-nasal disorder as such nor against GER solve the problem. 




improve the efficacy of LES. To what extent patients with reflux-induced CRS may 
benefit from such procedures remains unknown. It should be investigated.  
The pathophysiological link between GER, even proximal GER, and the local effects 
in the sino-nasal mucosa, has not been studied. Studies on animal models, healthy 
subjects or patients looking at the effects of esophageal perfusion of acid, non-acid 
gastric solutions or water on nasal mucosal blood flow, may give insight into the role 
of vasomotor reflexes. This is technically possible by using laser Doppler flowmetry.  
Based on the result in this thesis, it is reasonable to assume that reflux is involved in 
the pathogenesis of CRS in certain individuals. Awareness of this among doctors 
treating CRS-patients not responding to conventional treatment seems limited. Thus, 
some patients may be excluded from optimal treatment. This leaves a responsibility 
with the scientists behind these investigations to share this information in medical 
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Nasal and salivary pepsin as a biomarker for gastro-
esophageal reflux in chronic rhinosinusitis*
Abstract 
Background: Gastro-esophageal reflux (GER) may be a contributing factor for some patients with chronic rhinosinusitis (CRS). The 
aim of the present study was to investigate if Peptest, an immunoassay for pepsin detection, could be used as a biomarker for GER 
in CRS.
Methodology: Peptest was used to analyse 3 saliva and 3 nasal samples for pepsin A in 62 CRS-patients and 62 age and gender 
matched healthy controls. The results were correlated to 24-hour impedance pH-monitoring and symptom questionnaires.
Results: Patients with CRS did not have more abnormal Peptest measures compared to healthy controls, 39 patients and 48 
controls, respectively. The presence of abnormal Peptests did not correlate to proximal reflux in CRS-patients. Patients with high 
GerdQ scores did not have more positive Peptests than those without. 
Conclusions: These results question the value of Peptest as screening tool for GER in CRS.
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Introduction
Chronic rhinosinusitis (CRS) is a common chronic condition 
affecting up to 15 % of the adult population (1). It influences 
quality of life and working capacity by the inflammation of the 
mucosa of the nose and paranasal sinuses.  The aetiology of 
the inflammatory process is not completely understood, but a 
common hypothesis is that inappropriate immune responses to 
foreign agents results in CRS. Stimulation of T cells by Stap-
hylococcus aureus protected in biofilms is an example of such 
immune response. Whether severe cases of non-allergic rhinitis, 
allergic rhinitis, occupational rhinitis and CRS not responding 
to conventional treatment, could share a common underlying 
pathophysiology, is unclear (2). 
The lack of etiological clues impairs the development of evi-
dence based therapeutic strategies. The high number of patients 
with CRS failing to respond to medical and surgical treatment 
represents a major challenge both for the individual patients as 
such, but also for general practitioners as well as for specialists, 
and for society in general.
The role of Gastro-esophageal Reflux (GER) in upper airway 
disorders including CRS has been debated for decades (3-5). GER 
has an established role in the pathogenesis of dental erosions 
(6), asthma (7), chronic cough (8), laryngitis (9) and possibly also in 
chronic otitis media (10). Its role in CRS is unclear (3, 11, 12). In the Eu-
ropean Position Paper on Rhinosinusitis and Nasal Polyps 2012 
(EPOS 2012) it is therefore stated that more research is needed 
to enlighten the role of GER in CRS (13). 
In a recent study, we demonstrated that patients with gastro 
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esophageal reflux disease (GERD) had high scores on SNOT-20, 
a questionnaire for sino-nasal quality of life (14). In another study, 
we found that abnormal gastroesophageal reflux was signifi-
cantly more prevalent in CRS-patients than in healthy subjects 
as evaluated by 24 -hour esophageal impedance pH monitoring, 
the gold standard for the investigation of GER (15).
Twenty-four-hour impedance pH-monitoring is a resource-
demanding procedure, and not easily available. Alternative 
diagnostic methods are pH- monitoring only or endoscopic 
examinations. The former will not detect episodes of non-acid 
reflux, and the latter will only detect those with visible patho-
logy in the esophagus. Thus, it is warranted to find alternative 
and still valid methods for investigation of GER in CRS.
Reflux of gastric contents through the esophagus into the 
airways includes acid, pepsin, mucus, bile acids, pancreatic enzy-
mes, and remnants of food and drinks. Pepsin has been used as 
a diagnostic biomarker of GERD. A study of paediatric patients 
demonstrated an association between pepsin in saliva and 
findings at 24- hour impedance pH- monitoring (16). Also, pepsin 
concentrations in nasal lavage fluid were high, and correlated 
well with esophageal acid exposure (17). However, these results 
were not reproduced in another study which concluded that 
detection of salivary pepsin was an imprecise method at least 
for investigation of reflux in children with CRS (18).  
The aim of the present study was to evaluate if Peptest, a widely 
used immunoassay method for pepsin detection, could be used 
as a biomarker of GER in CRS. Furthermore, we wanted to eva-
luate if pepsin could be measured in nasal secretions and if so, 
compare the results with measures from healthy controls.
Methodology
Patients and healthy controls
This was a prospective controlled age and gender matched 
study, performed on an outpatient basis. Consecutive patients 
above 18 years of age, referred to the ENT department, Stavan-
ger University Hospital and diagnosed with CRS with or without 
polyps according to the EPOS 2012 criteria (13) were invited to 
participate. Sixty two CRS patients were included, 33 men and 
29 women. A similar number of age and gender matched heal-
thy controls were recruited at different jobs, among patient’s 
friends, neighbours, colleagues and among the investigator`s 
friends, family, colleagues and neighbours (Table 1). Median age 
in patients and healthy controls was 46 and 46.5 respectively 
(p=0.81). The same investigator handled all patients and healthy 
controls. 
Exclusion criteria were use of anti-reflux medication on a daily 
basis.  Symptoms of reflux were not an exclusion criteria per se. 
Nasal corticosteroids were not allowed the day of investigation. 
 
Peptest
Peptest® (RD Biomed Ltd, Cottingham, UK) is an enzyme linked 
immunoassay for detection of pepsin in saliva. This non-invasive 
test is based on a lateral flow device technology. It consists of 
antibodies to human pepsin and is specific to pepsin A, the 
isoform secreted only in the stomach (19, 20). A control band on 
the device indicates a correctly performed test and a second 
line indicates presence of pepsin, in the sample, defining a 
positive or negative test. The intensity of this line is proportio-
nal to the quantity of pepsin, and by using a reader, LFDR101, 
the concentration of pepsin in ng/mL is obtained (20). Both the 
sensitivity and specificity of Peptest has been claimed to be 87 
% (21), but recent meta-analysis suggests the sensitivity and the 
specificity to be lower, 64% and 65% respectively (22). The lower 
limit for detection of pepsin with Peptest is 16ng/ mL given by 
the manufacturer (20). To the best of our knowledge, Peptest has 
not previously been used on nasal secretions. 
CRS patients and healthy controls delivered 3 tubes with saliva 
and 3 tubes with nasal secretion (roughly 1 mL in each) for 
pepsin analysis. We strictly followed the recommendations from 
the manufacturers; “Sample one should be taken in an upright 
position within 15 minutes of waking up from overnight sleep 
before eating or brushing teeth, the second sample should be 
taken one hour following the main meal of the day and the third 
sample should be taken one hour following the next main meal 
of the day” (23). Subjects without rhinorrhoea used 0,5 mL sterile 
water for irrigation of each nostril to be able to deliver samples. 
The tubes for investigation contained 0,5 mL of 0,01 M citric acid 
for conservation, and the participants stored the samples in a 
refrigerator until analysis within 7 days, as recommended by the 
manufacturer (21). Each sample was centrifuged at 5000 rpm for 5 
minutes, 80 µl of the supernatant was extracted, and 240 µL mi-
gration buffer was added. This was vortex-mixed for 10 seconds 
before 80 µL was transferred to the pit of the Peptest device. 
The test was read as positive or negative after 15 minutes and 
quantification done by using the LFDR reader. 
The same investigator performed all the tests on both CRS 
patients and healthy control subjects.
Table 1. Subject characteristics.
CRS-patients Healthy controls
Age, years 46 46.5
Gender, men/ women 33/ 29 33/ 29
Smoking 10 1
BMI, median 25.1 25.9
Self-reported asthma 18 2
Ongoing treatment of reflux 0 0
Self-reported  allergy 16 8
CRS= Chronic rhinosinusitis, BMI= Body Mass Index
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24-hour combined pH-impedance monitoring
Forty-six patients completed 24-h combined pH-impedance mo-
nitoring, with recordings for 18 - 26 hours. The impedance pH-
catheter (ZAN-BG-44, Sandhill Scientific, Inc; Highland Ranch, 
CO, USA) was positioned trans-nasally into the oesophagus, 
with the proximal pH-electrode located 5 cm above the lower 
esophageal sphincter and the impedance electrodes 2, 4, 6, 8, 
10, 14, 16 and 18 cm above the lower esophageal sphincter (15). 
Questionnaires
Validated questionnaires were used to evaluate the clinical 
symptoms of GERD and CRS in patients and controls:
Visual Analogue Scale (VAS-CRS) is a psychometric response 
scale used to measure subjective sino-nasal symptoms (13). The 
20-item Sinonasal Outcome Test (SNOT-20) is a validated self- 
administered quality of life instrument specific for patients with 
symptoms of rhinosinusitis (24). The Gastro-Esophageal Reflux 
Disease Questionnaire (GerdQ) was used to record classical 
symptoms of GERD. It is a validated six item, self- administered 
questionnaire, scoring symptoms of reflux and dyspepsia sepa-
rately, with reflux symptoms increasing the score and dyspepsia 
decreasing it. Absence of any such symptoms gives a total score 
of 6 and scores above 8 indicate reflux disease (25). 
The Peptest scores were compared to GerdQ and VAS-CRS and 
SNOT-20. GerdQ, VAS-CRS and SNOT-20 in CRS-patients and 
healthy controls were also compared.
Statistical analysis
As data were not normally distributed, non-parametric statis-
tics was used. Summary statistics are reported as median and 
interquartile range (IQR) for continuous variables and numbers 
and percentages for categorical variables. Differences between 
patients and controls were examined using the paired samples 
Wilcoxon test for continuous data and McNemar test for cate-
gorical data. Correlations between variables where calculated 
using Spearman`s Rank Correlation (rho). 
The statistical analyses were done using SPSS ver. 24.0 (Statisti-
cal Package for Social Science, Chicago, IL, USA).
Ethics and approval
The study was conducted according to the guidelines laid down 
in the Declaration of Helsinki and all procedures were appro-
ved by Regional Norwegian Committee for Medical and Health 
Research Ethics approved the study (REK Vest 2010/2030).  All 
participants were included after written informed consent.
Results
Sixty-two CRS patients were included, 33 men and 29 women, 
and 62 controls (Table 1). There was no significant difference in 
Body Mass Index (BMI) between the CRS-patients and healthy 
subjects, median 25.1 and 25.9 respectively (p=0.46) (Table 1). 
Questionnaires were available for 60 matched pairs of patients 
and controls. Total GerdQ scores were not significantly higher in 
the CRS-patients compared to the healthy controls (p=0.25) but 
12 patients had GerdQ score ≥ 8, which is the level indicating 
GERD, compared to 3 in the control group (p=0.04) (Table 2). The 
patients had significantly higher SNOT-20 and VAS-CRS scores, 
compared to the controls (Table 2).
There was no significant difference in number of positive 
Figure 1. GerdQ scores in healthy controls and CRS-patients.
No significant difference in GerdQ, Gastroesophageal Reflux Disease 
Questionnaire, scores between CRS-patients and healthy controls, 
Wilcoxon, p=0.25. GerdQ is a validated six item, self- administered 
questionnaire, scoring symptoms of reflux and dyspepsia separately, 
with reflux symptoms increasing the score and dyspepsia decreas-
ing it.  Absence of any such symptoms gives a total score of six and 
scores above eight indicate reflux disease. Three healthy controls and 
12 patients had a GerdQ score ≥ 8, which is the level indicating GERD 
(p=0.08). CRS= Chronic rhinosinusitis.





GerdQ, median (IQR) 6 (5.3-7.0) 6 (5.5-6.0) 0.25*
Number participants 
















Questionnaires were available for 60 matched pairs of patients and 
controls. *Wilcoxon test for paired samples, **McNemar test for paired 
samples, CRS= Chronic rhinosinusitis, IQR= Interquartile Range, GerdQ= 
Gastroesophageal Reflux Disease Questionnaire, VAS-CRS = Visual 
Analogue Scale for chronic rhinosinusitis, SNOT-20= 20-item Sinonasal 
Outcome Test.
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salivary Peptests in patients and healthy controls (Table 3). 
Abnormal Peptest results in saliva samples, when defined as 
two or more positive Peptests or Peptest levels in one test ≥ 
100 ng was found in 39 patients and 48 controls (p= 0.08). The 
concentration of pepsin was significantly higher in the saliva of 
healthy controls compared to CRS-patients (Table 3, Figure 2). 
There were large variations in pepsin levels both in patients and 
controls, particularly in the latter.  
There was significantly higher number of positive Peptests in 
the second postprandial nasal sample in patients compared to 
healthy controls (p=0.02), but not in the other samples (Table 3), 
and the levels of pepsin in nasal samples did not differ between 
the two groups (Table 3, Figure 2).
There was no significant difference in number of positive Pep-
tests between patients with abnormal proximal reflux compared 
to those without (p=0.94) (Figure 3), and no correlation between 
the number of positive Peptests and number of proximal reflux 
(Spearman rho 0.13, p=0.42), nor between the number of posi-
tive Peptests and number of distal acid reflux episodes (Spear-
man rho 0.06, p=0.71). CRS patients with high GerdQ scores 
did not show higher concentration of pepsin in saliva or nasal 
secretion and number of positive tests was not significantly 
different between the two groups (p= 0.71). There was no cor-
relation between GerdQ scores and number of positive Peptest 
in the healthy controls (Spearman rho 0.17, p=0.18) or patients 
(Spearman rho 0.15, p=0.24).
Discussion
In this study we have demonstrated that patients with CRS did 
not have more pepsin A in saliva or nasal secretions as measu-
red by Peptest compared to healthy controls. CRS patients with 
abnormal proximal reflux did not have more samples positive 
for Peptest than patients without.  As a group, there were more 
patients with high GerdQ scores for classical GERD symptoms 
compared to the healthy controls. However, less than 40% of 
patients with EER may have the classical symptoms of reflux, 
Figure 3. Total number of Peptest positive samples per CRS-patient with 
and without proximal reflux, diagnosed with 24-hour pH-impedance 
monitoring. There was no significant difference, p= 0.94.
Figure 2. Pepsin concentration in nasal secretion and saliva in healthy controls and CRS-patients. Pepsin level in nasal secretion and saliva measured 
one hour after two different meals and within fifteen minutes after waking up in the morning. There were no significant differences in pepsin concen-
tration in nasal samples between CRS-patients and healthy controls, but significantly higher pepsin concentration in saliva in healthy control subjects 
compared to CRS-patients, paired sample Wilcoxon test. The concentrations are square root transformed for improved readability.
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meaning that the questionnaire does not have an important role 
in the evaluation of these conditions. Patients with high GerdQ 
scores or verified proximal reflux did not have more positive 
Peptests than the controls. These findings question the validity 
of the Peptest in the evaluation of GER in CRS.
Pepsin is a proteolytic enzyme responsible for digestion of pro-
teins in the stomach.  As pepsin A originates from pepsinogen 
secreted from gastric chief cells in the stomach, the finding of 
pepsin A in the esophagus, mouth or respiratory tract should be 
a diagnostic marker of reflux (26). The nasal mucosa has limited 
protective capacity against the refluxate, and could be more 
sensitive to its injurious influence (12). Pepsin is most harmful in 
its acidic state. However, it can cause injury with a pH up to 6,5 
and is not irreversibly denatured until  pH reaches 8. This implies 
that when pH in refluxate is above 4, and thus not detected by 
pH monitoring, there can still be active pepsin in the refluxate. 
Besides, theoretically, inactive pepsin can be reactivated and 
become harmful by a decrease in pH due to acid drinking or 
later acidic reflux events (27). 
The high number of positive Peptests in both patients and 
healthy controls in this study supports the concept of physio-
logical, mainly postprandial reflux. Every healthy individual 
refluxes small amounts of gastric contents, mainly after meals, 
most of them without having symptoms, and without having 
GERD (11). Less is known about reflux to the airways in healthy 
subjects. The high number of positive Peptests both in those 
with and without CRS may indicate individual differences in 
sensitivity to refluxate including pepsin, i.e. a certain level of 
pepsin may create disease in some individuals, but not in others. 
This theory has been supported by pH- impedance monitoring 
of the esophagus combined with symptom registration, with an 
estimation of Symptom Association Probability (SAP). SAP gives 
an indication of a time correlation between symptoms and re-
flux episodes, and it has been shown that exposure to refluxate 
that normally is considered physiological, may give symptoms in 
some patients (28). Thus, it may be speculated whether the same 
differences in vulnerability also exists in the nose, whether a cer-
tain level of pepsin may contribute to the development of CRS 
in certain predisposed individuals, but not in others. The lower 
concentration of pepsin in patients compared to  controls may 
partly be explained by gastroesophageal reflux inducing hyper 
salivation (29). The phenomenon has also been described in heal-
thy persons when stimulating the esophagus with hydrochloric 
acid (30). Hyper-salivation may dilute the concentration of pepsin 
in patients and thus act as a confounder in this study.
Peptest is supposed to give snapshot-information about the 
presence or absence of pepsin in saliva and nasal secretions. 
The concentration of pepsin in saliva varies during the day and 
decreases rapidly after an episode of reflux (31). Thus, saliva sam-
ples should be obtained soon after reflux events to detect the 
pepsin (16). Inappropriate timing can reduce real-life sensitivity of 
the Peptest though it has high technical sensitivity (32). Reflux ap-
pears mostly after meals, and corresponding symptoms of GERD 
is significantly highest 1 to 2 hours post-prandially (31). In the 
present study, we tested for pepsin 3 times a day, determined by 
time of waking up and time of meals and not by symptomatic 
reflux episodes. Hence, there could be episodes of reflux not 
detected with Peptest both in CRS-patients and controls, most 
likely more frequently in the former. That this is a valid assump-
tion is supported by the fact that pH-impedance of the esopha-
Number of positive Peptests (%) Pepsin concentration, ng/ mL, median (IQR)
CRS-patients Healthy controls P* CRS-patients Healthy controls P**
First postprandial saliva 
sample
35 (67.3) 34 (65.4) 1.00 31.0 (10.0-101.0) 128.0 (24.3-282.0) 0.02
Second postprandial saliva 
sample
34 (60.7) 37 (66.1) 0.69 35.5 (8.5-68.3) 161.5 (21.5-278.5) <0.001
Morning saliva sample 30 (51.7) 27 (46.6) 0.71 23.5 (6,0-68.3) 36.0 (0.0- 238.5) 0.03
First postprandial  nose sample 27 (47.4) 17 (29.8%) 0.11 12.5 (3.3-58.8) 6.5 (0.0-93.3) 0.66
Second postprandial nose 
sample
26 (45.6) 13 (22.8) 0.02 12.0 (1.0- 42.1) 3.0 (0.0- 44.0) 0.99
Morning nose sample 26 (42.6) 17 (27.9) 0.15 15.0 (1,0-52.5) 5,0 (0,0-80.0) 0.75
Table 3. Pepsin concentration in saliva and nasal secretions, as measured with Peptest.
Peptest results in saliva and nose samples collected at three different times during a day in CRS patients and healthy controls. There were significantly 
more positive Peptests in CRS-patient`s second nasal postprandial sample but no significant difference between the other groups regarding number 
of positive tests. There was significantly higher pepsin concentration in saliva samples from healthy controls, but no significant difference in pepsin 
concentrations in nasal samples between CRS-patients and healthy controls regarding pepsin concentration. The number of paired samples available 
varies from 48 to 61. CRS= Chronic rhinosinusitis, IQR= Interquartile range, *Categorical data tested with McNemar test, ** Continuous data tested 
with Wilcoxon test.
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gus, monitoring gastro-esophageal reflux continuously over 
a prolonged period of time, demonstrated both an increased 
incidence and severity of reflux in CRS-patients (15). Then it may 
be discussed to what extent detection of refluxate of gastric 
content, including pepsin, in the esophagus implies its presence 
and pato-physiologic role even in the upper airways. For the 
time being, there is no conclusive answer to that question.
Two different pathophysiological mechanisms have been pro-
posed to explain how GERD may contribute to airway manifes-
tations, through a vagal reflex or a direct toxic effect. As to CRS, 
the theory is that a neuronally induced nasal mucosal oedema 
gives ostial obstruction (33). Our results,  with no important 
difference in pepsin in nasal secretions and saliva between CRS-
patients and controls and no significant difference in pepsin 
in nasal secretion or saliva samples between CRS patients with 
proximal reflux or not, may be  in line with this, though reser-
vations have to be made due to the limited  specificity of the 
Peptest.   
The present study raises important questions about the validity 
and utility of Peptest as a screening method for extra-esopha-
geal reflux as also discussed by others (22). One can also question 
its usefulness in diagnosing GERD in general, since patients with 
abnormal gastroesophageal reflux had no more positive tests 
than those without. We strictly followed the recommendations 
from the manufacturers and found high levels of pepsin in both 
CRS patients and healthy controls, with even significantly higher 
levels of pepsin in saliva in controls compared to patients. Ac-
cordingly, it appears unlikely that methodological flaws should 
affect the present results and explain the high levels of pepsin 
in the control group. As data being the basis for calculation 
of the specificity of the test varies, and tends to be lower than 
previously assumed (22), it is relevant to question the practical 
specificity of the test when used as a diagnostic tool for GERD 
in upper airway diseases. If Peptest had been a reliable method 
to diagnose extra esophageal manifestation of GERD, we would 
also expect more positive tests in patients having proximal 
reflux as evaluated by 24-h impedance pH monitoring com-
pared to those without. The fact that CRS-patients, even those 
with severe GER, did not have more pepsin in saliva and nasal 
secretion than control subjects, supports the speculations about 
the utility of Peptest in clinical practice. However, we cannot 
rule out that it may have a role in cases with classical symptoms 
of reflux, and where test samples can be collected immediately 
after a reflux episode. 
Conclusion
As measured by Peptest, we did not find more pepsin in saliva 
or nasal secretions in CRS- patients than in healthy controls, nor 
in those with those with high GerdQ scores or verified proximal 
reflux, indicating a limited validity of the Peptest as screening 
tool for GER in CRS. 
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